Ligand-drug conjugate including linker having tris structure

The Tris structure linker in ligand-drug conjugates addresses stability and delivery issues in antibody-drug conjugates, enabling efficient and selective drug delivery to cancer cells, reducing systemic toxicity and side effects.

JP2024160336AInactive Publication Date: 2024-11-13RIGACHEM BIOSCIENCES INC
View PDF 20 Cites 0 Cited by

Patent Information

Application Number
JP2024134436
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-04-29
Filing Date
2024-08-09
Publication Date
2024-11-13
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 2024160336000001
    Figure 2024160336000001
  • Figure 2024160336000002
    Figure 2024160336000002
  • Figure 2024160336000003
    Figure 2024160336000003
Patent Text Reader

Abstract

To provide a linker capable of efficiently, specifically and selectively delivering drugs to target cells, and to provide a ligand-drug conjugate having the linker.SOLUTION: The present invention pertains to a ligand-drug conjugate including: a ligand; a linker which is covalently linked to the ligand and includes a tris structure represented by a specific structural formula; and active agents covalently linked to the linker. In the ligand-drug conjugate, the active agents are linked by the tris structure of the linker, and thus a greater number of active agents can be connected through a single linker. Accordingly, a greater number of active agents per antibody binding can be delivered to target cells, and drugs and / or toxins can stably reach the target cells and effectively exhibit medicinal effects.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a ligand-drug conjugate containing a linker having a tris structure, and more particularly to a ligand-drug conjugate containing a linker having a tris structure that has high delivery efficiency of an active agent. [Background technology]

[0002] Cancer is a disease caused by abnormal growth masses due to the autonomous overgrowth of body tissues, resulting from unregulated cell growth in various tissues. Early stage tumors can be removed by surgery and radiation therapy, while metastatic tumors are usually treated with palliative care using chemotherapy drugs.

[0003] Most chemotherapeutic agents administered parenterally are administered systemically, which can result in unwanted side effects and, in severe cases, serious toxicity. For this reason, there has been a focus on developing new chemotherapeutic agents that can selectively deliver these agents to tumor cells or adjacent tissues, thereby both increasing efficacy and minimizing toxicity / side effects.

[0004] Antibody-drug conjugates (ADCs) are a new target-oriented technology that releases toxic substances inside cells after binding to antibodies that bind to antigens, killing cancer cells, etc. While minimizing the impact on healthy cells, ADCs accurately deliver drugs to targeted cancer cells and are released only under specific conditions, making them more effective than antibody therapeutics themselves and significantly reducing the risk of side effects compared to existing anticancer drugs.

[0005] Such antibody-drug conjugates are basically composed of "antibody-linker-low molecular weight drug (toxin)". Here, the linker not only plays a functional role of simply linking the antibody and the drug, but also stably delivers the antibody to the target cells during circulation in the body, and then the antibody-drug conjugate is taken up into the cells, and the drug dissociates smoothly due to the dissociation phenomenon between the antibody and the drug (e.g., the result of hydrolysis by an enzyme) to show its efficacy in the target cancer cells. That is, depending on the stability of the linker, the linker plays a very important role in terms of the efficacy of the antibody-drug conjugate and safety such as systemic toxicity (Non-Patent Document 1).

[0006] Linkers in antibody-drug conjugates can be broadly classified as non-cleavable or cleavable. Most non-cleavable linkers are attached to antibodies using thioethers containing antibody cysteines. Such non-cleavable linkers usually cannot be separated from the antibody in vivo, and their efficacy may be further reduced if ADC internalization is not good. In the case of the commonly used thiol-maleimide method, the antibody-drug conjugate is not stable, which may lead to dissociation of the drug from the conjugate before or after reaching the target cell.

[0007] Instead of chemically unstable linkers with limited stability at physiological extracellular conditions, such as hydrolazone and disulfide-based linkers, linkers that are stable at physiological extracellular conditions are needed, and linkers with high plasma stability are needed to improve therapeutic applicability, since the drug must not be released outside the cells, but only within the cells targeted by the antibody to which it is linked.

[0008] Cleavable linkers can be hydrolyzed, for example, by lysosomal enzymes. Cleavable linkers can also include disulfide bonds involving, for example, cysteines of an antibody. Linkers containing disulfide bonds that allow dissociation using thiol exchange reactions rely in part on uptake of the antibody-drug conjugate into the target cell and exposure of the disulfide to the reducing environment of the cytoplasm. However, the presence of various types of thiols (e.g., albumin and glutathione) in the blood can cause the drug to dissociate from the antibody before it reaches the target.

[0009] US Pat. No. 5,399,433 provides protein-active agent conjugates having an amino acid motif that can be recognized by isoprenoid transferase.

[0010] Patent Document 2 relates to an antibody-drug conjugate using a bispecific antibody and its uses, and discloses that the antibody-drug conjugate can be easily formed by binding a bivalent cotinine-peptide and drug conjugate to an anti-cotinine single-chain variable fragment without requiring a multi-step synthesis procedure. [Prior art documents] [Patent documents]

[0011] [Patent Document 1] Republic of Korea Publication Patent No. 10-2014-0035393 [Patent Document 2] Republic of Korea Publication Patent No. 2019-0023084 [Patent Document 3] U.S. Pat. No. 4,816,567 [Patent Document 4] U.S. Pat. No. 5,514,548 [Patent Document 5] U.S. Pat. No. 5,545,806 [Patent Document 6] U.S. Patent No. 5,569,825 [Patent Document 7] U.S. Pat. No. 5,591,669 [Patent Document 8] U.S. Pat. No. 5,545,807 [Patent Document 9] International Publication No. 97 / 17852 [Patent Document 10] European Patent No. 1391213 [Patent Document 11] US Patent Application Publication No. 2009 / 0105461 [Patent Document 12] U.S. Patent No. 5,225,539 [Patent Document 13] International Application US2016 / 063564 [Patent Document 14] International Application US2016 / 063595 [Patent Document 15] U.S. Pat. No. 5,635,483 [Patent Document 16] International Publication No. 2017 / 089895 [Patent Document 17] Republic of Korea Patent Publication No. 10-2018-0078329 [Non-patent literature]

[0012] [Non-Patent Document 1] Discovery Medicine 2010,10(53):329-39).85-8 2018-08-14 [Non-Patent Document 2] Hia, RK et al.,Chem.Rev.,109:5620(2009) [Non-Patent Document 3] Meldal, M & Tornoe, CW, Chem Rev., 108:2952 (2008) [Non-Patent Document 4] Kolb,HC et al.,Angew.Chemie Int.Ed.Engl.,40:2004(2001) [Non-Patent Document 5] Bell, IM, J. Med. Chem., 47(8):1869(2004)

Non-licensed Document 6

Non-licensed Document 7

Non-licensed literature 9

Non-licensed literature 10

Non-licensed Document 11

Non-licensed Document 12

Non-licensed Document 13

Non-licensed Document 14

Non-licensed Document 15

Non-licensed Document 16

Non-licensed Document 17

Non-licensed Document 18

Non-licensed Document 19

Non-licensed Document 20

Non-licensed Document 21

Non-licensed Document 22

Non-licensed Document 23

Non-licensed Document 24

Non-licensed Document 25

Non-licensed Document 26

Non-licensed Document 27

Non-licensed Document 28

Non-licensed Document 29

Non-licensed Document 30

Non-licensed Document 31

Non-licensed Document 32

Non-licensed Document 33

Non-licensed Document 34

Non-licensed Document 35

Non-licensed Document 36

Non-licensed Document 37

Non-licensed Document 38

Non-licensed Document 39

Non-licensed Document 40

[0013] An object of the present invention is to provide a linker having a tris structure that has a high transfer efficiency of an active agent, and a ligand-drug conjugate containing the linker.

[0014] An object of the present invention is to provide a pharmaceutical composition comprising a ligand-drug conjugate containing a linker having a tris structure and a method of treatment using said pharmaceutical composition. [Means for solving the problem]

[0015] One aspect of the present invention provides a linker for a ligand-drug conjugate comprising a tris structure represented by a specific structure.

[0016] Another aspect of the present invention provides a ligand-drug conjugate comprising: a ligand; a linker covalently linked to the ligand and including a Tris structure represented by a specific structural formula; and an active agent covalently linked to the linker.

[0017] Yet another aspect of the present invention provides a pharmaceutical composition for preventing or treating hyperproliferative, cancerous or angiogenic diseases, comprising as an active ingredient a ligand-drug conjugate or a pharma- ceutical acceptable salt or solvate thereof, the ligand-drug conjugate comprising a ligand, a linker covalently linked to the ligand and comprising a Tris structure represented by a specific structural formula, and an active agent covalently linked to the linker.

[0018] Yet another aspect of the invention provides a method of treating a hyperproliferative, cancer, or angiogenic disease in an individual by administering to the individual a pharmaceutical composition according to an embodiment of the invention. Effect of the Invention

[0019] The ligand-drug conjugate according to one embodiment of the present invention may include a linker containing a Tris structure. The Tris structure of the linker allows an active agent to be linked to a larger number of active agents via one linker. That is, a larger number of active agents can be delivered to a target cell per ligand bond.

[0020] The ligand-drug conjugate according to one embodiment of the present invention is capable of effectively, specifically and selectively delivering drugs.

[0021] The linker according to one embodiment of the present invention not only plays a functional role of linking a ligand and a drug, but also enables the linker to stably reach target cells during circulation in the body and allows the drug to be easily released after reaching the target cells.

[0022] In addition, the ligand-drug conjugate according to the present invention has excellent stability under physiological extracellular conditions, which allows the drug to be released only within the target cell, not outside the cell. The drug is stably bound to the ligand, and while maintaining in vivo stability, it can exhibit the desired cytotoxicity, and is particularly stable in plasma, and can also be stable during circulation in the body.

[0023] Furthermore, since the linker according to one embodiment of the present invention includes a trigger unit that can easily release a drug in a target cell to maximize its efficacy, the drug and / or toxin can stably reach the target cell and effectively exert its efficacy. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0024] DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Hereinafter, the present invention will be described in detail with reference to the accompanying drawings, in which: FIG.

[0025] However, the present invention may be embodied in many different forms and is not limited to the implementations and embodiments described herein. Throughout the specification of the present invention, when a part "includes" a certain element, this does not mean that other elements are excluded, and it means that other elements may be further included, unless otherwise specified.

[0026] The terms "about", "substantially", and the like used throughout the specification of the present invention are used to mean a numerical value or a value close to the numerical value when the manufacturing and material tolerances inherent in the mentioned meaning are given, and are used to prevent unscrupulous infringers from unfairly taking advantage of the contents of the disclosure in which precise or absolute numerical values ​​are mentioned in order to facilitate understanding of the present invention. The terms "step of" or "step of" used throughout the specification of the present application do not mean "step for".

[0027] Throughout the present specification, the term "combinations thereof" in Markush-style phrases refers to mixtures or combinations of one or more selected from the group of elements described in the Markush-style phrase, including one or more selected from the group of elements described above. Throughout the present specification, the reference to "A and / or B" means "A or B, or A and B."

[0028] The present invention relates to a linker that connects a ligand and a drug, a ligand-drug conjugate containing the linker, a pharmaceutical composition for preventing or treating hyperproliferative, cancer, or angiogenic diseases, comprising the ligand-drug conjugate, and a method for treating hyperproliferative, cancer, or angiogenic diseases by administering the pharmaceutical composition to an individual.

[0029] In one embodiment of the present invention, a ligand is a molecule that can bind to a receptor present inside or outside a cell and can form a complex with a target biomolecule. Examples of ligands include molecules that bind to a predetermined position of a target protein to transmit a signal. For example, a ligand may be a protein, a substrate, an inhibitor, a promoter, a neurotransmitter, or a radioisotope.

[0030] In one embodiment of the invention, the ligand may be an antibody. As one skilled in the art will appreciate, the antibody of the antibody-drug conjugate described in one embodiment of the invention may be replaced by any suitable ligand.

[0031] Additionally, references and discussions relating to antibody-drug conjugates according to one embodiment of the present invention may be understood to be equally applicable to ligand-drug conjugates and their corresponding intermediates (e.g., ligand-linker conjugates), where not inconsistent with the nature.

[0032] Also, the ligand-drug conjugate according to one embodiment of the present invention may be understood to be the same as the ligand-drug conjugate.

[0033] One aspect of the present invention provides a linker comprising a Tris structure. According to one embodiment of the present invention, a linker linking a ligand and a drug (hereinafter also referred to as a "linker for ligand-drug conjugate" or "linker") may comprise a Tris structure (trifunctional), which allows multiple active agents to be conjugated to an antibody via the linker.

[0034] According to one embodiment of the present invention, the tris structure may be represented by the following general formula 1A:

[0035] [ka]

[0036] According to one embodiment of the present invention, the linker may include a first linker that is bound to an active agent and a second linker that is linked to an antibody, and the first linker and / or the second linker may include a tris structure represented by general formula 1A.

[0037] According to one embodiment of the present invention, the linker containing a tris structure may contain two or more branched linkers (BL1, BL2, BL3) via the tris structure.

[0038] According to one embodiment of the present invention, the tris structure may be represented by the following general formula 2A:

[0039] [ka]

[0040] According to one embodiment of the present invention, the linker may include a first linker that is linked to the nitrogen of the tris structure and is bound to an active agent, and a second linker (SL) that is bound to an antibody. The first linker may be understood to include two or more branched linkers (BL1, BL2, BL3) including the tris structure. The second linker (SL) can be bound to an antibody.

[0041] Furthermore, according to one embodiment of the present invention, the two or more branched linkers (BL1, BL2, BL3) and / or the second linker may include a tris structure represented by general formula 1A.

[0042] The branched linkers (BL1, BL2, BL3) may be covalently linked to an active agent. Each branched linker may be linked to one or more active agents. In one embodiment, any one of the three branched linkers (BL1, BL2, BL3) may not be linked to an active agent. Even within the same branched linker, the active agents may be the same or different from each other, and the active agents on different branched linkers may be the same or different from each other. It should be noted that even on the same antibody, the active agents linked to branched linkers may be the same or different from each other.

[0043] According to one embodiment of the present invention, any one of the branched linkers (BL3) may be hydrogen and may be represented by the following general formula 3A:

[0044] [ka]

[0045] According to one embodiment of the present invention, the tris structure may be represented by the following general formula 4A:

[0046] [ka]

[0047] According to one embodiment of the present invention, the tris structure may be represented by the following general formula 5A:

[0048] [ka]

[0049] According to one embodiment of the present invention, the linker may include a first linker containing nitrogen of a tris structure and a second linker (SL) linked to the antibody. The first linker may be understood to include two or more branched linkers (BL1, BL2, BL3) including a tris structure. The second linker (SL) can be bound to the antibody. The branched linkers (BL1, BL2, BL3) may be covalently linked to an active agent. Each branched linker can be bound to one or more active agents. In one embodiment, any one of the three branched linkers (BL1, BL2, BL3) may not be linked to an active agent. Even within the same branched linker, the active agents may be the same or different from each other, and the active agents on different branched linkers may be the same or different from each other. It should be noted that even on the same antibody, the active agents bound to the branched linkers may be the same or different from each other.

[0050] According to one embodiment of the present invention, any one of the branched linkers (BL3) may be hydrogen and may be represented by the following general formula 6A:

[0051] [ka]

[0052] According to one embodiment of the invention, the first linker (or the branched linker) and / or the second linker may comprise a polyethylene glycol unit.

[0053] In one embodiment, the three branched linkers (BL1, BL2, BL3) and the second linker (SL) may both contain polyethylene glycol units.

[0054] In one embodiment, the two branched linkers (any two of BL1, BL2, and BL3) and the second linker (SL) may contain polyethylene glycol units. Such combinations are not limited thereto and can be modified in various ways.

[0055] According to one embodiment of the invention, the first linker (or branched linker) and / or the second linker may include an atom such as nitrogen, and the first linker (or branched linker) and / or the second linker may include any atom or group that allows three bonds, such as an amine, a tertiary amide, or a tertiary or quaternary carbon.

[0056] In one embodiment, the first linker (or branched linker) and / or the second linker may be an amine or amino acid having a side chain with a group that can participate in an amide or ester bond.

[0057] In one embodiment of the present invention, the amide may be represented by the following general formula 14: [ka] Here, R 10 may be hydrogen or a substituted or unsubstituted alkyl having 1 to 5 carbon atoms.

[0058] In one embodiment, the first linker (or branched linker) and / or the second linker may comprise an amide.

[0059] In one embodiment, the branched linker may comprise an amide.

[0060] In one embodiment, the first linker, the second linker, and / or the branched linker may include naturally occurring or unnatural amino acids, in one embodiment, L-amino acids or D-amino acids, and in one embodiment, α-amino acids or β-amino acids.

[0061] For example, the amino acid may be selected from the group consisting of lysine, 5-hydroxylysine, 4-oxallysine, 4-thialysine, 4-selenalysine, 4-thiahomolysine, 5,5-dimethyllysine, 5,5-difluorolysine, trans-4-dehydrolysine, 2,6-diamino-4-hexanoic acid, cis-4-dehydrolysine, 6-N-methyllysine, diaminopimelic acid, ornithine, 3-methylornithine, α-methylornithine, citrulline, and homocitrulline.

[0062] In one embodiment, the first linker, the second linker, and / or the branched linker may comprise a lysine unit, which may also include modifications such as methylation of the ε-amino group, provision of methyl-, dimethyl-, and trimethyllysine, and acetylation, sumoylation, and / or ubiquitination.

[0063] According to one embodiment of the present invention, the first linker (or the branched linker) and / or the second linker may include a maleimide unit represented by the following general formula 1G:

[0064] [ka]

[0065] According to one embodiment of the present invention, the first linker (or branched linker) and / or the second linker may contain a substituted or unsubstituted alkylene having 1 to 100 carbon atoms, specifically 20 to 80 carbon atoms, and may satisfy one or more, specifically two or more of the following conditions (i) to (iv): (i) alkylene contains at least one unsaturated bond, specifically, 3 or 4 double or triple bonds; (ii) the alkylene contains at least one heteroarylene; (iii) at least one carbon atom of the alkylene is replaced by one or more heteroatoms selected from nitrogen (N), oxygen (O) and sulfur (S), specifically at least one nitrogen and at least one oxygen (e.g., in an oxime); and (iv) Alkylene is substituted with one or more alkyl having 1 to 20 carbon atoms, preferably with two or three methyl.

[0066] In one embodiment of the present invention, the linker may include a branching unit, a linking unit, a binding unit, a trigger unit, and an isoprenyl unit, which will be described in detail below.

[0067] One aspect of the invention provides a ligand-drug conjugate comprising a ligand, a linker covalently linked to the ligand, the linker comprising a Tris structure, and an active agent covalently linked to the linker.

[0068] The present invention relates to a linker that connects a ligand and a drug, a ligand-drug conjugate containing the linker, a pharmaceutical composition for preventing or treating hyperproliferative, cancer, or angiogenic diseases, comprising the ligand-drug conjugate, and a method for treating hyperproliferative, cancer, or angiogenic diseases by administering the pharmaceutical composition to an individual.

[0069] In one embodiment of the present invention, the ligand may be an antibody. As will be appreciated by those skilled in the art, the antibody of the antibody-drug conjugates (ADCs) described in one embodiment of the present invention may be replaced with any suitable ligand, and the ligand-drug conjugates described below may be understood to be equally applicable to antibody-drug conjugates.

[0070] According to one embodiment of the present invention, the linker may include a tris structure represented by the general formula 1A. The above description of the linker for the ligand-drug conjugate may be applied to the ligand-drug conjugate. The description of the linker described below may also be applied to the linker for the ligand-drug conjugate.

[0071] In one embodiment of the invention, the linker can be attached to the C-terminus of the antibody (eg, to the heavy and light chains of the antibody).

[0072] In one embodiment of the present invention, the linker may comprise a Branching unit (BR), a connection unit, or a Binding Unit.

[0073] In one embodiment, the linking unit can link the drug to the branching unit or the binding unit. Also, the linking unit can link the branching unit to the binding unit. Furthermore, the branching unit can be linked to the binding unit without the linking unit, and the binding unit or the linking unit can be linked to the antibody.

[0074] In one embodiment, the first linker (or branched linker) and / or the second linker may comprise a branching unit (BR), a connection unit, or a binding unit.

[0075] In one embodiment, the first linker and the second linker may comprise one or more Branching units (BR), connection units, or binding units.

[0076] In one embodiment, the first linker may include one or more Branching units (BR), Connection units (CU), or Binding units (BU).

[0077] In one embodiment, the second linker may include one or more Connection units.

[0078] In one embodiment of the invention, the branching unit (BR) may be an amino acid.

[0079] In an embodiment, the branching unit may be a naturally-occurring amino acid or a non-naturally occurring amino acid.

[0080] In an embodiment, the branching unit may be an L-amino acid or a D-amino acid.

[0081] In an embodiment, the branching unit may be an α-amino acid or a β-amino acid.

[0082] For example, the amino acid may be selected from the group consisting of lysine, 5-hydroxylysine, 4-oxallysine, 4-thialysine, 4-selenalysine, 4-thiahomolysine, 5,5-dimethyllysine, 5,5-difluorolysine, trans-4-dehydrolysine, 2,6-diamino-4-hexanoic acid, cis-4-dehydrolysine, 6-N-methyllysine, diaminopimelic acid, ornithine, 3-methylornithine, α-methylornithine, citrulline, and homocitrulline.

[0083] In one embodiment, the branching unit may be a hydrophilic amino acid, for example, the hydrophilic amino acid may be arginine, aspartic acid, asparagine, glutamic acid, glutamine, histidine, lysine, ornithine, proline, serine, or threonine.

[0084] In one embodiment, a hydrophilic amino acid can be an amino acid that contains a side chain with a residue that carries a charge in aqueous solution at neutral pH.

[0085] In one embodiment, the hydrophilic amino acid may be aspartic acid or glutamic acid.

[0086] In one embodiment, the hydrophilic amino acid may be ornithine or lysine.

[0087] In one embodiment, the hydrophilic amino acid may be arginine.

[0088] In one embodiment, the branching unit may comprise a lysine unit, which may also include modifications such as methylation of the ε-amino group, provision of methyl-, dimethyl- and trimethyllysine, and acetylation, sumoylation, and / or ubiquitination.

[0089] In one embodiment of the present invention, the branching unit (BR) may be hydrogen or an alkylene having 1 to 100 carbon atoms, specifically, 20 to 80 carbon atoms.

[0090] Here, the carbon atoms of the alkylene may be substituted with one or more heteroatoms selected from the group consisting of N, O and S, and the alkylene may be further substituted with one or more alkyls having 1 to 20 carbon atoms.

[0091] In one embodiment, the branching unit comprises a nitrogen-containing 1-50 atom heteroalkylene and two or more atoms of a hydrophilic amino acid, wherein the nitrogen is capable of forming a peptide bond with a carbonyl of the hydrophilic amino acid.

[0092] In one embodiment of the present invention, the branching unit (BR) is -C(O)-, -C(O)NR'-, -C(O)O-, -S(O)NR'-, -P(O)R"NR'-, -S(O)NR'-, or -PONR'-, where R' and R" are each independently hydrogen, (C-C) alkyl, (C-C) cycloalkyl, (C-C) alkoxy, (C-C) alkylthio, mono- or di-(C-C) alkylamino, (C-C 20 )heteroaryl, or (C6-C 20 ) aryl.

[0093] In one embodiment, the branching unit is -C(O)NR'-, where R' may be hydrogen.

[0094] In one embodiment of the present invention, the branching unit (BR) may be represented by any one of the following general formulas 1B to 8B.

[0095] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka]

[0096] In the general formulae 1B to 8B, L1, L2, and L3 are each independently a direct bond or -C n H 2n -, n is an integer from 1 to 30, G1, G2, and G3 each independently represent a direct bond, the following general formula 1, the following general formula 2, the following general formula 3, or the following general formula 4; R3 represents hydrogen or C1-C 30 alkyl, R4 is hydrogen or -L4-COOR5, L4 is a direct bond or -C n H 2n -, n is an integer from 1 to 10, and R5 is hydrogen or C1-C 30 It is an alkyl.

[0097] [ka] [ka] [ka] [ka]

[0098] In one embodiment of the present invention, the branching unit (BR) may be an oxime or an O-substituted oxime.

[0099] In one embodiment of the present invention, the branching unit (BR) may be represented by the following general formula 9B or 10B:

[0100] [ka] [ka]

[0101] In one embodiment of the present invention, the linking unit (CU) is -(CH2) r (V(CH2) p ) q --, --((CH2) p V) q --, --(CH2) r (V(CH2) p ) q Y-,-((CH2) p V) q (CH2) r ―,―Y((CH2) p V) q -- or -- (CH2) r (V(CH2) p ) q In this case, r is an integer of 0 to 10, p is an integer of 1 to 10, q is an integer of 1 to 20, and V and Y each independently represent a single bond, —O—, —S—, or —NR 21 --, --C(O)NR 22 --, --NR 23 C(O)―,―NR 24 SO2- or -SO2NR 25 - and R 21 ~R 25 are each independently hydrogen, (C1-C6) alkyl, (C1-C6) alkyl(C6-C 20 )aryl or (C1-C6)alkyl (C3-C 20 ) heteroaryl.

[0102] In one embodiment, r may be 2.

[0103] In one embodiment, p may be 2.

[0104] In one embodiment, q may be an integer from 6 to 20.

[0105] In one embodiment, q can be 2, 5, or 11.

[0106] In one embodiment, V and Y may each independently be —O—.

[0107] In one embodiment, the linking unit is -(CH2) r (V(CH2) p ) q In one embodiment, r may be an integer from 0 to 10, p may be an integer from 0 to 12, q may be an integer from 1 to 20, and V may be a single bond, -O-, or -S-. In one embodiment, r may be 2. In one embodiment, p may be 2. In one embodiment, q may be an integer from 6 to 20.

[0108] In one embodiment, V is —O—, r is 2, p is 2 and q may be 2, 5 or 11.

[0109] In one embodiment of the present invention, the linking unit (CU) may be a polyalkylene glycol unit, more specifically, a polyethylene glycol unit or a polypropylene glycol unit.

[0110] The polyethylene glycol unit may have a structure of the following general formula 5 or the following general formula 6: [ka] [ka]

[0111] In one embodiment of the present invention, the linking unit may have 1 to 12 -OCH2CH2- units, or 5 to 12 -OCH2CH2- units, or 6 to 12 -OCH2CH2- units.

[0112] In one embodiment of the invention, the linking unit may be -(CH2CH2X)w-, where X is a single bond, -O-, (C1-C8)alkylene, or -NR 21 - and R21 is hydrogen, (C1-C6) alkyl, (C1-C6) alkyl(C6-C 20 )aryl, or (C1-C6)alkyl (C3-C 20 ) heteroaryl, and w is an integer from 1 to 20, specifically 1, 3, 6, or 12.

[0113] In one embodiment, X may be —O— and w may be an integer from 6-20.

[0114] In one embodiment of the present invention, the linking unit (BU) may be formed by a 1,3-dipolar cycloaddition reaction, a hetero-Diels-Alder reaction, a nucleophilic substitution reaction, a non-aldol type carbonyl reaction, an addition to a carbon-carbon multiple bond, an oxidation reaction or a click reaction.

[0115] In one embodiment of the present invention, the linking unit (BU) may be formed by the reaction of an acetylene with an azide, or a non-aldol type carbonyl reaction, for example, the reaction of an aldehyde or ketone group with a hydrazine or an alkoxyamine.

[0116] In one embodiment of the present invention, the linking unit (BU) may be represented by any one of the following general formulas 1D to 4D.

[0117] [ka] [ka] [ka] [ka]

[0118] In the general formulae 1D to 4D, L1 is a single bond or an alkylene having 1 to 30 carbon atoms; R 11 is hydrogen or alkyl having 1 to 10 carbon atoms, specifically methyl; L2 is an alkylene having 1 to 30 carbon atoms.

[0119] In one embodiment of the present invention, the linker may include any one of units of the following general formulae 4A to 6A.

[0120] [ka] [ka] [ka]

[0121] In the general formulae 4A to 6A, V is a single bond, —O—, —S—, —NR 21 --, --C(O)NR 22 --, --NR 23 C(O)―,―NR 24 SO2- or -SO2NR 25 -, preferably -O-, R 21 ~R 25 are each independently hydrogen, (C1-C6) alkyl, (C1-C6) alkyl(C6-C 20 )aryl, or (C1-C6)alkyl (C3-C 20 ) heteroaryl, r is an integer from 1 to 10, preferably 2 or 3; p is an integer of 0 to 10, preferably 1 or 2; q is an integer of 1 to 20, preferably an integer of 1 to 6; L1 is a single bond.

[0122] In one embodiment of the present invention, click chemistry can be performed under mild conditions that can be performed in the presence of antibodies without modifying the antibodies. Click chemistry shows high reaction specificity. Thus, even though antibodies have various functional groups (e.g., amine, carboxyl, carboxamide, and guanidinium), click chemistry can be performed without affecting, for example, the amino acid side chains of antibodies. Click chemistry between azide and acetylene groups can occur in the presence of antibodies without modifying the amino acid side chains of antibodies. In some cases, reactants are selected to improve the overall reaction efficiency. For example, azide-acetylene click chemistry can produce triazoles in high yields (see, for example, Non-Patent Documents 1 to 3, each of which is incorporated herein by reference).

[0123] Azide and acetylene functional groups are not present in natural proteins, therefore, neither amino acid side chains, N-terminal amines, nor C-terminal carboxyls can be affected by click chemistry reactions using these functional groups.

[0124] In one embodiment of the present invention, the linking unit (BU) may be a polyalkylene glycol unit, more specifically, a polyethylene glycol unit or a polypropylene glycol unit.

[0125] The polyethylene glycol unit may have a structure of the following general formula 5 or the following general formula 6: [ka] [ka]

[0126] In one embodiment of the present invention, the linking unit may have 1 to 12 -OCH2CH2- units, or 5 to 12 -OCH2CH2- units, or 6 to 12 -OCH2CH2- units.

[0127] In one embodiment of the present invention, the linking unit (BU) may be a maleimide unit represented by the following general formula 1G:

[0128] [ka]

[0129] In one embodiment of the invention, the linker may further comprise an isoprenyl unit.

[0130] The isoprenyl unit may be represented by the following general formula 7 (wherein n is an integer of 2 or more): [ka]

[0131] In one embodiment of the invention, the isoprenyl unit is a substrate for an isoprenoid transferase or a product of an isoprenoid transferase.

[0132] In one embodiment of the invention, the isoprenyl unit of the linker is covalently attached to the antibody by a thioether bond, wherein the thioether bond involves a sulfur atom of a cysteine ​​of the antibody.

[0133] A cysteine ​​of the antibody, for example, at the C-terminus of the antibody heavy or light chain, can form a thioether bond with a carbon atom of the isoprenyl unit, thereby covalently linking the antibody to the linker.

[0134] Thus, in one embodiment, the linker may contain one isoprenyl unit, specifically two isoprenyl units, represented by the general formula 1E below, which may be recognized by an isoprenoid transferase, for example, as part of a product or substrate of the isoprenoid transferase.

[0135] [ka]

[0136] In one embodiment, the branching unit comprises an oxime and the isoprenyl unit is capable of covalently linking the oxime to the antibody.

[0137] In one embodiment of the invention, the linker is covalently attached to the ligand by a thioether bond, which may involve the sulfur atom of a cysteine ​​of the ligand.

[0138] In one embodiment of the present invention, the ligand may comprise an amino acid motif that can be recognized by an isoprenoid transferase. For example, the C-terminus of at least one antibody may comprise an amino acid motif that can be recognized by an isoprenoid transferase (e.g., as a substrate prior to forming a ligand-drug complex, or, e.g., as a product after forming a ligand-drug complex). The ligand may further comprise a spacer, such as an amino acid or stretch of amino acids that links the peptide chain of the antibody to the amino acid motif. The spacer may be composed of 1 to 20 consecutive amino acids, in particular, 7 or more amino acids. Glycine and proline are preferred amino acids for the spacer, and any combination of a series of about 7 glycines may be used.

[0139] In one embodiment, the C-terminus of the Ligand comprises the amino acid sequence GGGGGGCVIM. The Ligand may also contain additions or deletions to the carboxy terminus, e.g., relative to a form of the Ligand that is not included in a Ligand-Drug Conjugate.

[0140] Examples of isoprenoid transferases include farnesyl protein transferase (FTase) and geranylgeranyl transferase (GGTase), which can catalyze the transfer of a farnesyl or geranyl-geranyl group to at least one C-terminal cysteine ​​of a target protein. GGTases can be classified as GGTaseI or GGTaseII. FTase and GGTaseI can recognize a CAAX motif, and GGTaseII can recognize a XXCC, XCXC, or CXX motif, where C represents cysteine, A represents an aliphatic amino acid (e.g., isoleucine, valine, methionine, leucine), and each X independently represents, for example, glutamine, glutamic acid, serine, cysteine, methionine, alanine, or leucine (see Non-Patent Documents 7 to 10, each of which is incorporated herein by reference in its entirety).

[0141] The ligand-drug conjugates of the present invention may contain an amino acid motif, such as CYYX, XXCC, XCXC, or CXX, preferably CYYX, where C represents cysteine, Y represents, independently, an aliphatic amino acid, such as leucine, isoleucine, valine, and / or methionine, and X represents an amino acid that determines the substrate specificity of isoprenoid transferase, such as glutamine, glutamic acid, serine, cysteine, methionine, alanine, and / or leucine.

[0142] Isoprenoid transferases from a variety of sources can be used. For example, isoprenoid transferases can be obtained from humans, animals, plants, bacteria, viruses, or other sources. In some embodiments, naturally occurring isoprenoid transferases are used. In some embodiments, naturally or artificially modified isoprenoid transferases can be used. For example, the isoprenoid transferases can / may contain one or more amino acid substitutions, additions, and / or deletions, or the isoprenoid transferases can be modified by the addition of at least one of a histidine-tag, GST, GFP, MBP, CBP, Isopeptag, BCCP, Myc-tag, calmodulin-tag, FLAG-tag, HA-tag, maltose binding protein-tag, Nus-tag, glutathione-S-transferase-tag, green fluorescent protein-tag, thioredoxin-tag, S-tag, Softag 1, Softag 3, Strep-tag, SBP-tag, Ty-tag, and the like.

[0143] Isoprenoid transferase recognizes an isosubstrate and / or a substrate. Terminology isosubstrate refers to a substrate analogue that includes a chemical modification. Isoprenoid transferase can alkylate specific amino acid motifs (e.g., CAAX motifs) at the C-terminus of an antibody (see, e.g., Non-Patent Documents 11 to 14, each of which is incorporated herein by reference in its entirety). Functionalized antibodies can be generated using an isoprenoid transferase and an isosubstrate that can alkylate a C-terminal cysteine.

[0144] In one embodiment, the isosubstrate may be a compound represented by the general formula 2E below:

[0145] [ka]

[0146] The cysteine ​​of the C-terminal CAAX motif may be coupled to an isosubstrate using an isoprenoid transferase.

[0147] In one embodiment, a portion of the motif, e.g., AAX, may be sequentially removed, e.g., by a protease, leaving only the isoprenoid-bound cysteine, which may be optionally methylated, e.g., enzymatically, at the carboxyl terminus (see, e.g., J. Am. Soc. 1999, 143:1311-1323, which is incorporated herein by reference in its entirety).

[0148] According to one embodiment of the invention, the active agent may be linked to the linker through a cleavable or non-cleavable bond, hydrolyzable or non-hydrolyzable bond. In one embodiment of the invention, the active agent may be linked to a first linker, e.g., a branched linker (BL1, (BL2, BL3).

[0149] In one embodiment of the invention, the active agent may be linked to the linker with a Trigger Unit (TU), which may be understood to be a self-immolative group that is cleaved to release the active agent from the ADCs.

[0150] In one embodiment of the present invention, the trigger unit may be represented by the following general formula 1F:

[0151] [ka]

[0152] In the above formula, G is a sugar, sugar acid, or sugar derivatives; W is —C(O)—, —C(O)NR'—, —C(O)O—, —S(O)NR'—, —P(O)R''NR'—, —S(O)NR'—, or —PO2NR'—, and when C(O), S, or P is directly attached to a phenyl ring, R' and R'' are each independently hydrogen, (C1-C8)alkyl, (C3-C8)cycloalkyl, (C1-C8)alkoxy, (C1-C8)alkylthio, mono- or di-(C1-C8)alkylamino, (C3-C 20 )heteroaryl, or (C6-C 20 ) aryl, each Z is independently hydrogen, (C1-C8) alkyl, halogen, cyano, or nitro; n is an integer from 1 to 3, m is 0 or 2; R1 and R2 are each independently hydrogen, (C1-C8) alkyl, or (C3-C8) cycloalkyl, or R1 and R2 together with the carbon atom to which they are attached form a (C3-C8) cycloalkyl ring; L represents a linker bond. The * indicates the site that is linked to an active agent (drug or toxin).

[0153] In one embodiment, the trigger unit may be represented by the following general formula 3F or general formula 4F:

[0154] [ka] [ka]

[0155] In one embodiment, the sugar or sugar acid may be a monosaccharide.

[0156] In one embodiment, G may be represented by the following general formula 2F:

[0157] [ka]

[0158] In the above general formula 2F, R3 is hydrogen or a carboxyl protecting group; Each R4 is independently hydrogen or a hydroxyl protecting group.

[0159] The carboxyl protecting group may be any suitable protecting group for masking a carboxylic acid during organic synthesis, for example, methyl, methoxymethyl, methylthiomethyl, tetrahydropyranyl, benzyloxymethyl, phenacyl, N-phthalimidomethyl, 2,2,2-trichloroethyl, 2-haloethyl, 2-(p-toluenesulfonyl)ethyl, t-butyl, cinnamyl, benzyl, triphenylmethyl, bis(o-nitrophenyl)methyl, 9-anthrylmethyl, 2-(9,10-dioxo)anthrylmethyl, piperonyl, 2-trimethylsilylethyl, trimethylsilyl, or t-butyldimethylsilyl. In one embodiment, the entire moiety R3-OC(=O)- may be replaced by a carboxyl-masking moiety such as 2-alkyl-1,3-oxazolinyl.

[0160] The hydroxyl protecting group may be any suitable protecting group for masking a hydroxyl group during organic synthesis, such as acetyl, methyl, ethoxyethyl, benzoyl, benzyl, 4-methoxybenzyl, 3,4-dimethoxybenzyl, tetrahydropyranyl (THP), tetrahydrofuranyl (THF), tert-butyldimethylsilyl (TBDMS), trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), tert-butyldiphenylsilyl (TBDPS), triisopropylsilyloxymethyl (TOM), β-methoxyethoxymethyl (MEM), methoxymethyl (MOM), allyl or trityl.

[0161] In one embodiment, R3 in formula 2F above may be hydrogen and each R4 may be hydrogen.

[0162] In one embodiment, W of general formula 1F is -C(O)NR'-, where C(O) is linked to a phenyl ring and NR' may be linked to a linker, e.g., a first linker (or a branched linker).

[0163] In one embodiment, Z in formula 1F above may be hydrogen and n may be 3.

[0164] In one embodiment, R1 and R2 in general formula 1F may each be hydrogen.

[0165] In one embodiment, the trigger unit may be represented by the general formula 1F, W is -C(O)NR'-, where C(O) is linked to a phenyl ring, NR' is linked to a first linker (or a branched linker), each Z is hydrogen, n is 3, m is 1, and R1 and R2 are each hydrogen. In this case, G may be a compound represented by the general formula 2F.

[0166] In one embodiment of the invention, the active agent may be a chemotherapeutic agent or a toxin. The active agent may be a drug, a toxin, an affinity ligand, a detection probe, or a combination of any of these.

[0167] The active agent may also be an immunomodulatory compound, an anti-cancer agent, an anti-viral agent, an anti-bacterial agent, an anti-fungal agent, an anti-parasitic agent, or a combination thereof, and may be selectively used from among the active agents listed below:

[0168] (a) erlotinib, bortezomib, fulvestrant, sutent, letrozole, imatinib mesylate, PTK787 / ZK 222584, oxaliplatin, 5-fluorouracil, leucovorin, rapamycin, lapatinib, lonafarnib, sorafenib, gefitinib, AG1478, AG1571, thiotepa, cyclophosphamide, busulfan, improsulfan, piposulfan, benzodopa, carboquone, meturedopa, uredopa, ethylenimine, a Altretamine, triethylenemelamine, trietylenephosphoramide, triethylenethiophosphoramide, trimethylolomelamine, bullatacin, bullatacinone, camptothecin, topotecan, bryostatin, callystatin, CC-1065, adozelesin, carzelesin, bizelesin, cryptophycin 1 1), cryptophycin 8, dolastatin, duocarmycin, KW-2189, CB1-TM1, eleutherobin,Pancratistatin, sarcodictyin, spongistatin, chlorambucil, chlornaphazine, chlorophosphamide, estramustine, ifosfamide, mechlorethamine, melphalan, novembichin, fenestrone, Phenesterine, prednimustine, trofosfamide, uracil mustard, carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimnustine, calicheamicin, calicheamicin gamma 1 gamma 1, calicheamicin omega 1, dynemicin, dynemicin A, clodronate, esperamicin, neocarzinostatinchromophore, aclacinomysins, actinomycin, antimycin, azaserine, bleomycins, cactinomycin, carabicin, carninomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubucin,6-diazo-5-oxo-L-norleucine, doxorubicin, morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin, liposomal doxorubicin, deoxydoxorubicin, epirubicin, esorubicin, marcellomycin, mitomycin C C), mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptomigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin, 5-fluorouracil , denopterin, methotrexate, pteropterin, trimetrexate, fludarabine, 6-mercaptopurine, thiamiprine, thiguanine, ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine,Enocitabine, floxuridine, calusterone, dromostanolone, propionate, epithiostanol, mepitiostane, testolactone, aminoglutethimide, mitotane, trilostane, folinic acid linicacid, aceglatone, aldophosphamideglycoside, aminolevulinic acid, eniluracil, amsacrine, bestrabucil, bisantrene, edatraxate, defofamine, demecolcine, diaziquone diaziquone, elfornithine, elliptinium acetate, etoglucid, gallium nitrate, hydroxyurea, lentinan, lonidainine, maytansine, ansamitocins, mitoguazone, mitoxantrone ), mopidanmol, nitraerine, pentostatin, phenamet, pirarubicin, losoxantrone, 2-ethylhydrazide, procarbazine, polysaccharide-k, razoxane, rhizoxin, sizofiran,Spirogermanium, tenuazonic acid, triaziquone, 2,2',2''-trichlorotriethylamine, T-2 toxin, verracurin A, roridin A A), anguidine, urethane, vindesine, dacarbazine, mannomustine, mitobronitol, mitolactol, pipobroman, gacytosine, arabinoside, cyclophosphamide, thiotepa, paclitaxel, paclitaxel, albumin-engineered nanoparticle formulation of paclitaxel, docetaxel, chlorambucil, gemcitabine, 6-thioguanine, mercaptopurine, cisplatin, carboplatin (c arboplatin, vinblastine, platinum, etoposide, ifosfamide, mitoxantrone, vincristine, vinorelbine, novantrone, teniposide, edatrexate, daunomycin, aminopterin, xeloda, ibandronate, CPT-11, topoisomerase inhibitor RFS2000, difluoromethylornithine, retinoic acid, capecitabine, or a pharma- ceutically acceptable salt, solvate, or acid thereof; (b) monokine, lymphokine, traditional polypeptide hormone, parathyroid hormone, thyroxine, relaxin, prorelaxin, glycoprotein hormone, follicle stimulating hormone, thyroid stimulating hormone, luteinizing hormone, hepatic growth factor, fibroblast growth factor, prolactin, placental lactogen, tumor necrosis factor-α, tumor necrosis factor-β, mullerian-inhibiting substance, mouse gonadotropin-associated peptide peptide), inhibin, activin, vascular endothelial growth factor, thrombopoietin, erythropoietin, osteoinductive factor, interferon, interferon-α, interferon-β, interferon-γ, colony stimulating factor;CSF, macrophage-CSF, granulocyte-macrophage-CSF, granulocyte-CSF, interleukin (IL), IL-1, IL-1α, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, tumor necrosis factor, TNF-α, TNF-β, polypeptide factor, LIF, kit ligand, or combinations thereof; (c) diphtheria toxin, botulinum toxin, tetanus toxin, dysenteriatoxin, cholera toxin, amanitin, α-amanitin, pyrrolobenzodiazepines, pyrrolobenzodiazepine derivatives, tetrodotoxin, brevetoxin, ciguatoxin, ricin, AM toxin, auristatin, tubulysin, geldanamycin, maytansinoids, calicheamycin, daunomycin, doxorubicin, methotrexate, vindesine, SG2285, dolasatin, dolasatin analogs analog, auristatin, cryptophycin, camptothecin, rhizoxin, rhizoxin derivatives, CC-1065, CC-1065, analogs or derivatives, duocarmycin, enediyne antibiotic, esperamicin, epothilone, toxoid, or combinations thereof; (d) an affinity ligand, wherein the affinity ligand is a substrate, an inhibitor, an activator, a neurotransmitter, a radioisotope, or a combination thereof; (e) a radioactive label, 32P, 35S, a fluorescent dye, an electron densere agent, an enzyme, biotin, streptavidin, digoxigenin, a hapten, an immunogenic protein, a nucleic acid molecule with a sequence complementary to a target, or a combination thereof; (f) immunomodulatory compounds, anti-cancer agents, anti-viral agents, anti-bacterial agents, anti-fungal agents, and anti-parasitic agents, or combinations thereof; (g) tamoxifen, raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, or toremifene; (h)4(5)—imidazole, aminoglutethimide, megestrol acetate, exemestane, letrozole, or anastrozole; (i) flutamide, nilutamide, bicalutamide, leuprolide, goserelin, or troxacitabine; (j) aromatase inhibitors; (k) protein kinase inhibitors; (l) lipid kinase inhibitors; (m) shRNA, siRNA, PNA or antisense oligonucleotide; (n) ribozyme; (o) Vaccines; (p) anti-angiogenic agents, and (q) Immuno-oncology therapeutic agents.

[0169] The immuno-anticancer agent may be selected from an antibody, a peptide, a protein, a small molecule, an adjuvant, a cytokine, an oncolytic virus, a vaccine, a bi-specific molecule, a cell therapy, a checkpoint inhibitor, a STING agonist, an adenosine receptor antagonist, and combinations thereof. The checkpoint inhibitor may be an inhibitor of a receptor selected from PD-1, PD-L1, and CTLA-4.

[0170] In one embodiment of the present invention, the activator may be any one of the following general formulas: 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or 31:

[0171] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka]

[0172] Here, y is an integer from 1 to 10.

[0173] In one embodiment, the linker may be represented by any one of the structures of the following general formulas 32 to 37. The * symbol indicates the site that is linked to the active agent (drug or toxin).

[0174] [ka] [ka] [ka] [ka] [ka] [ka]

[0175] The ligand-drug conjugate according to one embodiment of the present invention may be prepared using methods known in the art, including molecular biology and cell biology methods. For example, transient or stable transfection may be used. Gene sequences encoding specific amino acid motifs that can be recognized by isoprenoid transferase can be inserted into known plasmid vectors using standard PCR and / or ligation techniques to express antibodies with specific amino acid motifs at the C-terminus. Thus, antibodies with at least one or more amino acid motifs that can be recognized by isoprenoid transferase can be expressed in a suitable host, such as CHO cells or E. coli.

[0176] In another aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating hyperproliferative, cancer or angiogenic diseases comprising the ligand-drug conjugate or a pharma- ceutically acceptable salt or solvate thereof as an active ingredient.

[0177] The cancer may be selected from the group consisting of lung cancer, small cell lung cancer, gastrointestinal cancer, colon cancer, intestinal cancer, breast cancer, ovarian cancer, prostate cancer, testicular cancer, liver cancer, kidney cancer, bladder cancer, pancreatic cancer, brain cancer, sarcoma, osteosarcoma, Kaposi's sarcoma, and malignant melanoma.

[0178] The ligand-drug conjugates may be used to deliver active agents to target cells in an individual to treat the individual.

[0179] The compositions may be made into injectable forms, either as liquid solutions or suspensions, or in solid forms suitable for injection, for example as emulsions, or with the ligand-drug complex encapsulated in liposomes.

[0180] In one embodiment of the invention, the ligand-drug conjugate may be formulated with a pharma- ceutically acceptable carrier, including any carrier that does not induce the production of antibodies in the individual to whom the carrier is administered. Suitable carriers typically include macromolecules that are slowly metabolized, such as, for example, proteins, polysaccharide conjugates, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, lipid aggregates, and the like.

[0181] The composition may contain diluents, such as water, saline, glycerol and ethanol. Auxiliary substances may also be present, such as wetting or emulsifying agents, pH buffering substances, and the like. The composition may be administered parenterally by injection, which may be subcutaneous or intramuscular. In some embodiments, the composition may be administered intratumorally. The composition may be inserted (e.g., injected) into a tumor. Additional dosage forms are suitable for other types of administration, such as, for example, by suppositories or orally. Oral compositions may be administered as solutions, suspensions, tablets, pills, capsules, or sustained release dosage forms.

[0182] The compositions may be administered in any manner compatible with the dosage form and dosage form.

[0183] The composition may further comprise a therapeutically effective amount of a chemical therapeutic agent, hi one embodiment, the composition may be administered in combination with one or more anti-hyperproliferative, cytostatic or cytotoxic agents.

[0184] The terminology "therapeutically effective amount" refers to a composition administered in a single dose, or in a multiple dose schedule, effective to treat or prevent a disease or disorder. The amount administered will vary depending on the individual to be treated, the individual's health and physical condition, the degree of protection desired, and other relevant factors. The precise amount of active ingredient (e.g., antibody-drug conjugate) is at the discretion of the physician. For example, a therapeutically effective amount of an antibody-drug conjugate or a composition containing the same can be administered to a patient suffering from cancer or a tumor to treat the cancer or tumor.

[0185] The ligand-drug conjugates of the present invention or compositions containing them may be administered in the form of a pharma- ceutically acceptable salt or solvate thereof.

[0186] In one embodiment, the ligand-drug conjugates of the present invention or compositions containing them may be administered with a pharma- ceutically acceptable carrier, a pharma- ceutically acceptable vehicle, and / or a pharma- ceutically acceptable additive. The effective amount and type of pharma- ceutically acceptable salt or solvate, vehicle, and additive may be determined using standard methods (see, for example, J. Med. Soc. 1999, 143:131-135).

[0187] The term "therapeutically effective amount" refers to an amount capable of reducing the number of cancer cells, reducing the size of cancer cells, inhibiting or reducing the invasion of cancer cells into surrounding systems, inhibiting or reducing the spread of cancer cells to other systems, inhibiting the growth of cancer cells, or ameliorating one or more symptoms associated with cancer. In treating cancer, the effectiveness of a drug can be assayed by tumor-to-tumor progression (TTP) and / or response rate (RR).

[0188] The terminology "pharmaceutically acceptable salt" as used herein includes organic and inorganic salts, examples of which include, but are not limited to, hydrochloride, hydrobromide, hydroiodide, sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acidic phosphate, isonicotinate, lactate, salicylate, acid citrate, and the like. citrate, tartrate, oleate, tannate, pantonate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methane sulfonate, ethane sulfonate, benzene sulfonate, p-toluene sulfonate Pharmaceutically acceptable salts include the following: sulfonate, and pamoate (i.e., 1,1'-methylenebis-(2-hydroxy-3-naphthoate). Pharmaceutically acceptable salts may contain other molecules, such as acetate ions, succinate ions, and other counter ions.

[0189] Examples of solvates that may be used as pharma- ceutically acceptable solvates of the ligand-drug conjugates of the present invention include, but are not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine.

[0190] In yet another aspect of the present invention, there is provided a method for treating cancer in an individual by administering to the individual a pharmaceutical composition for preventing or treating a hyperproliferative, cancer or angiogenic disease comprising a ligand-drug conjugate according to one embodiment of the present invention.

[0191] In one embodiment, the individual may be a mammal. For example, the individual may be selected from the group consisting of rodents, lagomorphs, felines, canines, porcines, ovines, bovines, equines, and primates. In one embodiment, the individual may be a human.

[0192] [Definition] The term "antibody" refers to an immunoglobulin molecule that recognizes and specifically binds to other molecules through at least one antigen recognition site in the variable region of the immunoglobulin molecule. As used herein, the term "antibody" includes intact polyclonal antibodies, intact monoclonal antibodies, antibody fragments (e.g., Fab, Fab', F(ab')2, Fd, and Fv fragments), single-chain Fv (scFv) mutants, multispecific antibodies, e.g., bispecific antibodies generated from two or more intact antibodies, chimeric antibodies, humanized antibodies, human antibodies, fusion proteins containing an antigenic determinant of an antibody, and any other modified immunoglobulin molecule that contains an antigen recognition site. An antibody may be any of the five main immunoglobulin classes: IgA, IgD, IgE, IgG, and IgM, or subclasses (isotypes) thereof, based on the identity of the heavy chain constant domains, designated alpha (α), delta (Δ), epsilon (ε), gamma (γ), and mu (μ), respectively (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2). The different types of immunoglobulins have well-known subunit structures and three-dimensional structures that differ from one another. The terminology "antibody" does not refer to molecules that do not share homology with immunoglobulin sequences. For example, the terminology "antibody" as used herein does not include "repebodies."

[0193] The term "antibody fragment" refers to a portion of an intact antibody that represents the antigen-determining variable region of the intact antibody. Examples of antibody fragments include Fab, Fab', F(ab')2, Fd, and Fv fragments, linear antibodies, single-chain antibodies, and multispecific antibodies formed from antibody fragments.

[0194] The term "monoclonal antibody" refers to a homogenous antibody population that recognizes and binds to a single antigenic determinant or epitope with high specificity. This is in contrast to polyclonal antibodies, which typically contain other antibodies against a variety of different antigenic determinants. The term "monoclonal antibody" includes, but is not limited to, antibody fragments (e.g., Fab, Fab', F(ab')2, Fd, and Fv), single chain (scFv) mutants, fusion proteins containing antibody moieties, and any other modified immunoglobulin molecule that contains both an intact full-length monoclonal antibody as well as an antigen recognition site. Additionally, "monoclonal antibody" refers to an antibody produced by any number of methods, including but not limited to hybridoma, phage selection, recombinant expression, and transgenic animals.

[0195] The term "humanized antibody" refers to a form of a non-human (e.g., murine) antibody that is a specific immunoglobulin chain, a chimeric immunoglobulin, or a fragment thereof that contains minimal non-human (e.g., murine) sequence. Typically, a humanized antibody is a human immunoglobulin in which the complementarity determining regions (CDRs) have been replaced with residues from the CDRs of a non-human species (e.g., mouse, rat, rabbit, and hamster) that has the desired specificity, affinity, and binding capacity (see, for example, Non-Patent Documents 15 to 17). In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced with the corresponding residues of an antibody from a non-human species that has the desired specificity, affinity, and binding capacity. The humanized antibody may be further modified by substituting additional residues within the Fv framework regions and / or the replaced non-human residues to improve and optimize the antibody specificity, affinity, and / or binding capacity. Usually, a humanized antibody essentially comprises at least one, typically two or three, variable domains that contain all or substantially all of the CDRs corresponding to a non-human immunoglobulin, while having all or substantially all of the framework region (FR) human immunoglobulin consensus sequence. A humanized antibody may also comprise at least a portion of an immunoglobulin constant region or domain (Fc), typically a portion of a human immunoglobulin. Examples of methods used to generate humanized antibodies are described in U.S. Patent No. 5,225,539, which is incorporated herein by reference.

[0196] The terminology "human antibody" as used herein refers to an antibody that is encoded by a human nucleotide sequence or an antibody having an amino acid sequence that corresponds to an antibody made by a human being using any technique known in the art. This definition of a human antibody includes full-length antibodies and / or fragments thereof.

[0197] The term "chimeric antibody" refers to an antibody in which the amino acid sequence of the immunoglobulin molecule originates from two or more species, one of which is preferably human. Usually, the variable regions of the light and heavy chains correspond to the variable regions of an antibody originating from one mammalian species (e.g. mouse, rat, rabbit, etc.) having the desired specificity, affinity and binding capacity, while the constant regions are homologous to the sequences of antibodies originating from another species (usually human), e.g. to avoid eliciting an immune response in said species.

[0198] The terminology "epitope" and "antigenic determinant" are used interchangeably herein to refer to a portion of an antigen that can be recognized and specifically bound by a particular antibody. When an antigen is or includes a polypeptide or protein, an epitope may be formed from juxtaposed, contiguous and / or non-contiguous amino acids, for example, by secondary, tertiary and / or quaternary folding of the protein. Epitopes formed from contiguous amino acids are typically preserved upon denaturation of the protein, whereas epitopes formed by tertiary folding may be lost upon denaturation of the protein. An epitope typically includes 3 or more, 5 or more, or 8-10 or more amino acids in a unique spatial conformation.

[0199] By "specifically binding" an antibody to an epitope or antigenic molecule, it is meant that the antibody interacts or associates with the epitope or antigenic molecule more frequently, more rapidly, for a longer period of time, with greater affinity, or with some combination of the above properties, than with alternatives, including unrelated proteins. In some embodiments, "specifically binding" means, for example, that the antibody binds to the protein with a KD of about 0.1 mM or less, more typically less than about 1 μM. In certain embodiments, "specifically binding" means that the antibody binds to the protein with a KD of about 0.1 μM or less, and at other times with a KD of about 0.01 μM or less. Due to sequence homology between homologous proteins in different species, specific binding may include an antibody that recognizes a particular protein in more than one species. It is understood that an antibody or binding moiety that specifically binds to a first target may or may not specifically bind to a second target. As noted above, "specific binding" does not necessarily require (although it may include) exclusive binding, i.e., binding to a single target. Usually, but not necessarily, the terminology "binding" as used herein refers to specific binding.

[0200] The fragments / derivatives and antibodies, including monoclonal antibodies, can be obtained using methods known in the art (see Non-Patent Documents 18 to 35, and Patent Documents 3 to 9, all of which are incorporated herein by reference in their entirety).

[0201] The antibodies include muromonab-CD3 abciximab, rituximab, daclizumab, palivizumab, infliximab, trastuzumab, etanercept, basiliximab, gemtuzumab, and alemtuzumab. mtuzumab, ibritumomab, adalimumab, alefacept, omalizumab, efalizumab, tositumomab, cetuximab, ABT-806, bevacizumab, natalizumab atalizumab, ranibizumab, panitumumab, eculizumab, rilonacept, certolizumab, romiplostim, AMG-531, golimumab, ustekinumab, ABT-874, belatacept, belimumab, atacicept, anti-CD20 antibodies, canakinumab, tocilizumab, atlizumab, mepolizumab, pertuzumab, HuMax CD20CD20, tremelimumab, ticilimumab, ipilimumab, anti-CTLA-4 antibody, IDEC-114, inotuzumab, HuMaxEGFR, aflibercept, HuMax-CD4, teplizumab, otelixizumab, catumaxomab, anti-EpCAM antibody IGN101 IGN101, adecatumomab, oregovomab, dinutuximab, girentuximab, denosumab, bapineuzumab, motavizumab, efumgumab, raxibacumab, anti-CD20 The antibody may be LY2469298, Pembrolizumab, Nivolumab, Pidilizumab, anti-PD-1 antibody, BMS-936559, Durvalumab, Avelumab, Atezolizumab, MDX-1105, anti-PD-L1 antibody, and veltuzumab.

[0202] When the antibody comprises at least one light chain and at least one heavy chain, at least one light chain of the antibody, or at least one heavy chain of the antibody, or both may comprise an amino acid region having an amino acid motif that can be recognized by an isoprenoid transferase. Since the antibody may comprise four polypeptide chains (e.g., two heavy chains and two light chains), the antibody may comprise four amino acid motifs, each of which is used to conjugate an active agent to the antibody via a linker. Thus, the antibody-drug conjugate comprises four linkers, each of which is conjugated to at least one active agent. Thus, the antibody-drug conjugate may comprise at least one linker and at least two active agents. The antibody-drug conjugate may comprise at least two linkers, and the antibody-drug conjugate may comprise at least three active agents. The antibody-drug conjugate may comprise one, two, three, or four linkers. The antibody-drug conjugate may comprise one, two, three, or four peptides. The antibody-drug conjugate may contain 2 to 100 conjugates, for example, 2 to 50 conjugates, 2 to 20 conjugates, 2 to 16 conjugates, 4 to 16 conjugates, or 4 to 8 conjugates.

[0203] The active agent may be a drug, a toxin, an affinity ligand, a detection probe, or a combination of any of these.

[0204] The active agents are erlotinib; bortezomib; fulvestrant; sutent; letrozole; imatinib mesylate; PTK787 / ZK 222584; oxaliplatin; 5-fluorouracil; leucovorin; rapamycin; lapatinib; lonafarnib; sorafenib; gefitinib; AG1478; AG1571; alkylating agents (e.g., thiotepa, cyclophosphamide); alkyl sulfonates (e.g., busulfan, improsulfan, piposulfan); aziridines (e.g., benzodopa, carboquone, meturedopa, uredopa); ethylenimine, methylmelamine lmelamine, altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, trimethylolomelamine; acetogenins (e.g., bullatacin or bullatacinone); camptothecin and camptothecin derivatives and metabolites (SN-38); topotecan; bryostatin; callystatin; CC-1065 (which may also be adozelesin, carzelesin, or bizelesin synthetic analogs)cryptophycins (e.g., cryptophycin 1 or cryptophycin 8); dolastatin; duocarmycins (e.g., synthetic analogs such as KW-2189 and CB1-TM1); eleutherobin; pancratistatin; sarcodictyin; spongistatin; nitrogen mustards (e.g., chlorambucil, chlornaphazine, chlorophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride). hydrochloride, melphalan, novembichine, phenesterine, prednimustine, trofosfamide, or uracil mustard; nitrosourea (e.g., carmustine, chlorozotocin, fotemustine, lomustine, nimustine, or ranimnustine); antibiotics (e.g., enediyne antibiotics such as calicheamicins selected from calicheamicin gamma II and calicheamicin omega II or dynemicin, including dynemicin A).antibiotics); bisphosphonates (e.g., clodronate; esperamicin, neocarzinostatin chromophore, or related chromoprotein enediyne antibiotic chromophores), aclacinomysins, actinomycin, anthramycin, azaserine, bleomycins, cactinomycin, carabicin, carninomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, daunorubicin, detorubucin, 6-diazo-5-oxo-L-norleucine, doxorubicin (e.g., morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin, liposomal doxorubicin, or deoxydoxorubicin), epirubicin, esorubicin, marcellomycin, mitomycins (e.g., mitomycin C),C), mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptomigrin, streptozocin, tubercidin, ubenimex, zinostatin, or zorubicin; anti-metabolites (e.g., 5-fluorouracil); folic acid analogs analogs (e.g., denopterin, methotrexate, pteropterin, and trimetrexate); purine analogs (e.g., fludarabine, 6-mercaptopurine, thiamiprine, or thiguanine); pyrimidine analogsanalogs (e.g., ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, or floxuridine); androgens (e.g., calcitabine, calusterone, dromostanolone propionate, epitiostanol, mepitiostane, or testolactone; anti-adrenals (such as aminoglutethimide, mitotane, and trilostane); folic acid supplements acid replenishers (e.g., folinic acid); aceglatone; aldophosphamideglycoside; aminolevulinic acid; eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elfornithine; elliptinium acetate; epothilone; etoglucid; gallium nitratenitrate; hydroxyurea; lentinan; lonidainine; maytansinoids (e.g., maytansine or ansamitocins); trichothecenes (especially T-2 toxin, verracurin A, roridin A, or anguidine); mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone; 2-ethylhydrazide; procarbazine; polysaccharide K complex complex); razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2"-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A, and anguidine); urethane; vindesine; dacarbazine; mannomustine; mitobronitol obronitol; mitolactol; pipobroman; gacytosine; arabinoside; cyclophosphamide; thiotepa; taxoids (e.g., paclitaxel), ABRAXANE™ (Cremophor-free), albumin-modified nanoparticle formulations of paclitaxel (ABRAXANE TM cremophor-free, albumin-engineered nanoparticle formulation of paclitaxel, doxetaxel; chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; platinum analogs (e.g., cisplatin, or carboplatin); vinblastine; platinum; etoposide; ifosfamide; mitoxantrone; vincristine ine); vinorelbine; novantrone; teniposide; edatrexate; daunomycin; aminopterin; xeloda; ibandronate; CPT-11; topoisomerase inhibitor (RFS2000); difluoromethylornithine; retinoids (e.g., retinoic acid); capecitabine, and pharma- ceutically acceptable salts, solvates, acids, or derivatives thereof. However, the present invention is not necessarily limited thereto.

[0205] Active agents include (i) antihormonal agents that modulate or inhibit hormone action in tumors, such as antiestrogens and selective estrogen receptor modulators, including, for example, tamoxifen, raloxifene, droloxifene, 4-hydroxytamoxifen, trioxyphene, ketoxifene, LY117018, onapristone, and toremifene; (ii) adrenal anti-inflammatory agents, such as, for example, 4(5)-imidazoles, aminoglutethimide, megestrol acetate, exemestane, letrozole, and anastrozole. (iii) antiandrogens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; as well as troxacitabine (a 1,3-dioxolane nucleoside cytosine analog); (iv) aromatase inhibitors; (v) protein kinase inhibitors; (vi) lipid kinase inhibitors; (vii) antisense oligonucleotides, particularly those used to treat adherent cell fibrosis; those that inhibit the expression of genes in signal transduction pathways associated with IL-19 (IL-19 cells), e.g., PKC-alpha, Raf, H-Ras; (viii) ribozymes, e.g., VEGF inhibitors such as ribozymes and HER2 expression inhibitors; (ix) vaccines, e.g., gene therapy vaccines; ALLOVECTIN® vaccine, LEUVECTIN® vaccine, VAXID® vaccine; PROLEUKIN® rlL-2; LURTOTECAN® topoisomerase 1 inhibitor; ABARELIX® rmRH; (x) angiogenesis inhibitors, such as Bevacizumab;and (xi) a pharma- ceutically acceptable salt, solvate, acid or derivative thereof;

[0206] Cytokines may also be used as active agents. Cytokines are small cell signaling protein molecules secreted by many cells and are a category of signaling molecules that are widely used in intercellular communication. Cytokines include monokines, lymphokines, and typical polypeptide hormones. Examples of cytokines include growth hormones (e.g., human growth hormone, N-methionyl human growth hormone, or bovine growth hormone); parathyroid hormone; thyroxine; insulin, proinsulin, relaxin; prorelaxin; glycoprotein hormones (e.g., follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), luteinizing hormone (LH); hepatic growth factor; fibroblast growth factor; prolactin; placental lactogen; tumor necrosis factor-α, tumor necrosis factor-β; mullerian-inhibiting substance; mouse gonadotropin-associated peptide (MGP). peptide); inhibin; activin; vascular endothelial growth factor; integrin, thrombopoietin (TPO); nerve growth factor (e.g., NGF-β); platelet-growth factor; transforming growth factor (TGF) (e.g., TGF-α or TGF-β);Insulin-like growth factor-I, insulin-like growth factor-II; erythropoietin (EPO); osteoinductive factor; interferon (e.g., interferon-α, interferon-β, or interferon-γ); colony stimulating factor (CSF) Examples of cytokines include, but are not limited to, macrophage-CSF (M-CSF), granulocyte-macrophage-CSF (GM-CSF), or granulocyte-CSF (G-CSF); interleukin (IL) (e.g., IL-1, IL-1α, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, or IL-12); tumor necrosis factor (TNF) (e.g., TNF-α or TNF-β); and polypeptide factor (e.g., LIF or Kit ligand). The terminology "cytokine" includes cytokines from natural sources or recombinant cell culture and biologically active equivalents of the native sequence cytokines;

[0207] The terminology "toxin" refers to a substance that is toxic to living cells or organisms. Toxins may be small molecules, peptides or proteins that can cause cell dysfunction or cell death after contacting or being absorbed into body tissues through interaction with one or more biological macromolecules, such as enzymes or cell receptors. Toxins include plant and animal toxins. Examples of animal toxins include, but are not limited to, diphtheria toxin, botulinum toxin, tetanus toxin, dysentery toxin, cholera toxin, tetrodotoxin, brevetoxin and ciguatoxin. Examples of plant toxins include, but are not limited to, ricin and AM-toxin.

[0208] Examples of compound toxins include auristatin, tubulysin, geldanamycin (Non-Patent Document 35), maytansinoids (Patent Document 10, Non-Patent Document 37), calicheamicin (Patent Document 11, Non-Patent Document 38), daunomycin, doxorubicin, methotrexate, vindesine, SG2285 (Non-Patent Document 38), dolastatin, and dolastatin analogs auristatin (Patent Document 15), cryptophycin, camptothecin, rhizoxinderivative, CC1065 analogs or derivatives, duocarmycin, enediyne antibiotic, esperamicin, epothilone, pyrrolobenzodiazepine (PBD) derivatives, α-amanitin, and toxoids, but are not limited to these. Toxins can exhibit cytotoxicity and cell growth-inhibitory activity through tubulin binding, DNA binding, topoisomerase inhibition, etc.

[0209] A "detectable moiety" or "label" refers to a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, radioactive, or chemical means. For example, useful labels include: 32 P, 35Detectable moieties include S, fluorescent dyes, electron-concentrating agents, enzymes (e.g., those commonly used in ELISA), biotin-streptavidin, digoxigenin, haptens, and proteins for which antisera or monoclonal antibodies are available, or nucleic acid molecules having a sequence complementary to the target. The detectable moiety often produces a measurable signal, e.g., a radioactive, chromogenic or fluorescent signal, that can be used to quantitate the amount of bound detectable moiety in a sample. Quantitation of the signal is accomplished, for example, by scintillation counting, densitometers, flow cell analysis, ELISA, or direct analysis of circular or subsequently digested peptides by mass spectrometry (one or more peptides may be assayed).

[0210] The term "probe" as used in this specification refers to a substance that can (i) provide a detectable signal, (ii) modify the detectable signal provided by the first or second probe by reacting the first or second probe with each other, such as by fluorescence resonance energy transfer (FRET), (iii) stabilize the interaction with an antigen or ligand or increase the binding affinity, (iv) affect the electromobility or cell-penetrating action by physical parameters such as charge, hydrophobicity, and (v) modulate the ligand affinity, antigen-antibody binding, or the formation of an ionic complex.

[0211] The active agents include immunomodulatory compounds, anti-cancer agents, anti-viral agents, anti-bacterial agents, anti-fungal agents, anti-parasitic agents or combinations thereof.

[0212] Immunomodulatory compounds include aminocaproic acid, azathioprine, bromocriptine, chlorambucil, chloroquine, cyclophosphamide, cyclosporine, cyclosporine A, danazol, dehydroepiandrosterone (DHEA), dexamethasone, etanercept, hydrocortisone, hydroxychloroquine, infliximab, meloxicam, methotrexate, mycophenolate mofetil, and cyclosporine A. The agent may be selected from mofetil, prednisone, sirolimus, and tacrolimus. Anticancer drugs include 1-methyl-4-phenylpyridinium ion, 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide (EICAR), 5-fluorouracil, 9-aminocamptothecin, actinomycin D, asparaginase, bicalutamide, bis-chloroethylnitrosourea (BCNU), bleomycin, bleomycin A2, bleomycin B2, and bleomycin B1.B2), busulfan, camptothecin, carboplatin, carmustine, CB1093, chlorambucil, cisplatin, crisnatol, cyclophosphamide, cytarabine, cytosine arabinoside, cytoxan, dacarbazine, dactinomycin, daunorubicin, decarbazine, deferoxamine, demethoxy-hypocrellin A A), docetaxel, doxifluridine, doxorubicin, EB1089, epirubicin, etoposide, floxuridine, fludarabine, flutamide, gemcitabine, goserelin, hydroxyurea, idarubicin, ifosfamide, interferon-α, interferon-γ, irinotecan, KH1060, leuprolide acetate acetate), lomustine, lovastatin, megestrol, melphalan, mercaptopurine, methotrexate, mitomycin, mitomycin C, mitoxantrone, mycophenolic acid, nitrogen mustardmustard, nitrosourea, paclitaxel, peplomycin, photosensitizer Pe4 Pe4), phthalocyanine, pirarubicin, plicamycin, procarbazine, raloxifene, raltitrexed, revlimid, ribavirin, staurosporine, tamoxifen, teniposide, thalomid, thapsigargin, thioguanine, thiazopurine, topotecan, treosulfan, trimetrexate, tumor necrosis factor Antiviral agents may be selected from pencicyclovir, valacyclovir, gancicyclovir, foscarnet, ribavirin, idoxuridine, vidarabine, trifluridine, acyclovir, famcicyclovir, amantadine, rimantadine, cidofovir, antisense oligonucleotides, ribavirin ...The antibacterial agent may be selected from chloramphenicol, vancomycin, metronidazole, trimethoprin, sulfamethazole, quinupristin, dalfopristin, rifampin, spectinomycin, and nitrofurantoin. The antifungal agent may be selected from amphotericin B.B), candicidin, filipin, hamycin, natamycin, nystatin, rimocidin, bifonazole, butoconazole, clotrimazole, econazole, fenticonazole, isoconazole, ketoconazole, luliconazole, miconazole, omoconazole, oxiconazole, sertaconazole, sulconazole zole, tioconazole, albaconazole, fluconazole, isavuconazole, itraconazole, posaconazole, ravuconazole, terconazole, voriconazole, abafungin, amorolfin, butenafine, naftifine, terbinafine, anidulafungin, caspofungin, micafungin, benzoic acid acid, ciclopirox, flucytosine, griseofulvin, haloprogin, tolnaftate, undecylenic acid, crystal violet, balsam of peru, ciclopirox olamine, piroctone olamineolamine, zinc pyrithione, and selenium sulfide. The antiparasitic agent may be selected from mebendazole, pyrantel pamoate, thiabendazole, diethylcarbamazine, ivermectin, niclosamide, praziquantel, albendazole, rifampin, amphotericin B, melarsoprol, eflornithine, metronidazole, tinidazole, and miltefosine.

[0213] The antibody may comprise an amino acid motif selected from Ab-HC-(G)zCVIM, Ab-HC-(G)zCVLL, Ab-LC-(G)zCVIM, and Ab-LC-(G)zCVLL, where Ab represents the antibody, -HC- represents the heavy chain, -LC- represents the light chain, G represents glycine, C represents cysteine, V represents valine, I represents isoleucine, M represents methionine, L represents leucine, and z represents an integer from 0 to 20.

[0214] The terminology "acyl" is art recognized and refers to a group represented by the general formula hydrocarbylC(O)--, preferably alkylC(O)--.

[0215] The terminology "acylamino" is art recognized and refers to an amino group substituted with an acyl group and may be represented, for example, by the general formula hydrocarbylC(O)NH--.

[0216] The terminology "acyloxy" is art recognized and refers to a group of the general formula hydrocarbylC(O)O--, preferably alkylC(O)O--.

[0217] The terminology "alkoxy" refers to an alkyl group, preferably a lower alkyl group, having an oxygen attached thereto. Representative examples of alkoxy groups include methoxy, ethoxy, propoxy, tert-butoxy, and the like.

[0218] The terminology "alkoxyalkyl" refers to an alkyl group substituted with an alkoxy group and may be represented by the general formula alkyl-O-alkyl.

[0219] The terminology "alkenyl" as used herein refers to one or more aliphatic groups and is intended to include both "unsubstituted alkenyl" and "substituted alkenyl", the latter of which refers to an alkenyl moiety having a substituent replacing a hydrogen on one or more carbons of the alkenyl group. Such a substitution may occur on one or more carbons that are either included or not included in one or more double bonds. Moreover, the substitution includes any of those contemplated for an alkyl group, as discussed below, except where stability prohibits. For example, alkenyl groups substituted with one or more alkyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups are contemplated.

[0220] An "alkyl" group or "alkane" is a fully saturated, straight-chain or branched, non-aromatic hydrocarbon. Typically, a straight-chain or branched alkyl group has 1 to 20 carbon atoms, preferably 1 to 10 carbon atoms, unless otherwise specified. Examples of straight-chain and branched alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, pentyl, hexyl, pentyl, and octyl. C1-C6 straight-chain or branched alkyl groups are also referred to as "lower alkyl" groups.

[0221] Additionally, the terminology "alkyl" (or "lower alkyl") as used throughout the specification, examples, and claims is intended to include both "unsubstituted alkyl" and "substituted alkyl," the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone, unless otherwise specified, which are halogen, hydroxyl, carbonyl (e.g., carboxyl, alkoxycarbonyl, formyl, or acyl), thiocarbonyl (e.g., thioester, thioacetate, or thioformate), alkoxyl, phosphoryl, phosphate, phosphonate, phosphinate, amino, amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, aralkyl, or aromatic or heteroaromatic moieties. It will be understood by those skilled in the art that the moieties substituted on the hydrocarbon chain can themselves be substituted, where appropriate. For example, substituted alkyl substituents can include ether, alkylthio, carbonyl (including ketones, aldehydes, carboxylates, and esters), -CF3, -CN, and the like, as well as substituted and unsubstituted forms of amino, azido, imino, amino, phosphoryl (including phosphonates and phosphinates), sulfonyl (including sulfates, sulfonamides, sulfamoyl, and sulfonates), and silyl groups. Exemplary substituted alkyls are set forth below. Cycloalkyls can be further substituted with alkyl, alkenyl, alkoxy, alkylthio, aminoalkyl, carbonyl-substituted alkyl, -CF3, -CN, and the like.

[0222] For example, when used in conjunction with chemical moieties such as acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy, the terminology "C x―y " means a group containing x to y carbons in the chain. For example, the terminology "C x―y"Alkyl" refers to substituted or unsubstituted saturated hydrocarbon groups including straight-chain alkyl and branched-chain alkyl groups containing x to y carbons in the chain, including haloalkyl groups such as trifluoromethyl and 2,2,2-trifluoroethyl. C0 alkyl indicates a hydrogen in the group's terminal position, or a bond if internal. The terminologies "C2-alkenyl" and "C2-alkynyl" refer to substituted or unsubstituted unsaturated aliphatic groups of approximately the same length, which may be substituted as above for alkyl, but which contain at least one double or triple bond, respectively.

[0223] The terminology "alkylamino" as used herein refers to an amino group substituted with at least one alkyl group.

[0224] The terminology "alkylthio" as used herein refers to a thiol group substituted with an alkyl group and may be represented by the general formula alkylS-.

[0225] The terminology "alkynyl" as used herein refers to an aliphatic group containing one or more triple bonds and is intended to include both "unsubstituted alkynyl" and "substituted alkynyl", the latter of which refers to an alkynyl moiety having substitutions replacing hydrogen on one or more carbons of the alkynyl group. Such substitutions can occur on one or more carbons that are either included or not included in one or more triple bonds. Such substitutions also include any of those contemplated for alkyl groups, as noted above, except where stability prohibits. For example, substitution of an alkynyl group with one or more alkyl, carbocyclyl, aryl, heterocyclyl, or heteroaryl groups is contemplated.

[0226] The terminology "amine" and "amino" are art-recognized and refer to all unsubstituted and substituted amines and salts thereof, which can be represented, for example, by the following general formula 38 or the following general formula 39: [ka] [ka]

[0227] Here, each R 10 are independently hydrogen or a hydrocarbyl group, or two R 10 together with the N atom to which they are attached complete a heterocycle having 4 to 8 atoms in the ring structure.

[0228] The terminology "aminoalkyl" as used herein refers to an alkyl group substituted with an amino group.

[0229] The terminology "carboxy" as used herein refers to a group represented by the general formula -CO2H.

[0230] The terminologies "hetaralkyl" and "heteroaralkyl" used herein refer to an alkyl group substituted with a hetaryl group.

[0231] The terminology "heteroalkyl" as used herein refers to a saturated or unsaturated chain having carbon atoms and at least one heteroatom, where no two heteroatoms are adjacent.

[0232] The terminologies "heteroaryl" and "hetaryl" include substituted or unsubstituted aromatic monocyclic structures, preferably 5- to 7-membered rings, more preferably 5- to 6-membered rings, in which the ring structure includes at least one heteroatom, preferably 1 to 4 heteroatoms, more preferably 1 or 2 heteroatoms. The terminologies "heteroaryl" and "hetaryl" also include polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjacent rings, in which at least one or more of the rings is heteroaromatic, e.g., the other cyclic rings are cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, and / or heterocyclyl. Heteroaryl groups include, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyridazine, and pyrimidine.

[0233] The terminology "heteroatom" as used in this specification means an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen and sulfur.

[0234] The terminologies "heterocyclyl", "heterocycle" and "heterocyclic ring" refer to a substituted or unsubstituted non-aromatic ring structure, preferably a 3- to 10-membered ring, more preferably a 3- to 7-membered ring, the ring structure containing at least one heteroatom, preferably 1 to 4 heteroatoms, more preferably 1 or 2 heteroatoms. The terminologies "heterocyclyl" and "heterocycle" also include polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjacent rings, where at least one or more of the rings is a heterocycle, for example, the other cyclic rings are cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, and / or heterocyclyl. Heterocyclyl groups include, for example, piperidine, piperazine, pyrrolidine, morpholine, lamtam, lamtam, etc. Heterocyclyl groups may also be substituted with oxo groups. For example, "heterocyclyl" includes both pyrrolidine and pyrrolidinone.

[0235] The terminology "hydroxyalkyl" as used herein refers to an alkyl group substituted with a hydroxy group.

[0236] The terminology "substituted" refers to a moiety having a substituent replacing a hydrogen on one or more carbons of the backbone. It should be understood that "substituted" or "substituted with" includes the implicit condition that such substitution, subject to the allowed valences of the substituted atom and substituent, results in a stable compound that does not spontaneously undergo changes, such as, for example, rearrangement, cyclization, elimination, etc. As used herein, the terminology "substituted" is intended to include all permissible substitutions of organic compounds.

[0237] In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds. The permissible substituents can be one or more and the same or different for suitable organic compounds. For purposes of this invention, heteroatoms such as nitrogen can have hydrogen substitutions and / or any permissible substitutions of organic compounds described herein that satisfy the valences of the heteroatoms. Substituted groups may include any of the substituents described herein, for example, halogen, hydroxyl, carbonyl (e.g., carboxyl, alkoxycarbonyl, formyl, or acyl), thiocarbonyl (e.g., thioester, thioacetate, or thioformate), alkoxyl, phosphoryl, phosphate, phosphonate, phosphinate, amino, amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, aralkyl, or aromatic or heteroaromatic moieties. One of ordinary skill in the art will recognize that, where necessary, a substituent may itself be substituted. Unless specifically designated as "unsubstituted," references herein to a chemical moiety are understood to include substituted modifications. For example, references to an "aryl" group or moiety are intended to encompass both substituted and unsubstituted modifications.

[0238] The terminology "thioalkyl" as used herein refers to an alkyl group substituted with a thiol group.

[0239] The term "thioester" used in this specification means -C(O)SR 10 Or - SC(O)R 10 Here, R 10 indicates hydrocarbyl.

[0240] The terminology "thioether" used herein is equivalent to an ether, where the oxygen is replaced by a sulfur.

[0241] A "protecting group" refers to an atomic group that, when attached to a reactive functional group in a molecule, masks, reduces or prevents the reactivity of the functional group. Usually, a protecting group may be selectively removed as needed during synthesis. Examples of protecting groups can be found in the literature [see: Greene and Wuts, Protective Groups in Organic Chemistry, 3rd Ed., 1999, John Wiley & Sons, NY and Harrison et al., Compendium of Synthetic Organic Methods, Vols. 1-8, 1971-1996, John Wiley & Sons, NY]. Representative nitrogen protecting groups include, but are not limited to, formyl, acetyl, trifluoroacetyl, benzyl, benzyloxycarbonyl ("CBZ"), tert-butoxycarbonyl ("BOC"), trimethylsilyl ("TMS"), 2-trimethylsilyl-ethanesulfonyl ("TES"), trityl and substituted trityl groups, allyloxycarbonyl, 9-fluorenylmethyloxycarbonyl ("FMOC"), nitro-veratryloxycarbonyl ("NVOC"), and the like. Representative hydroxyl protecting groups include, but are not limited to, alkyl ethers, tetrahydropyranyl ethers, trialkylsilyl ethers (e.g., TMS or TIPS groups), glycol ethers such as ethylene glycol and propylene glycol derivatives, and allyl ethers, as well as acylated (esterified) or alkylated hydroxyl groups such as benzyl and trityl ethers.

[0242] "Covalently linked / covalently bonded" includes both direct and indirect bonding of two chemical species (e.g., via an intervening series of atoms). For example, an amino acid can be covalently bonded directly to polyethylene glycol, e.g., by forming an ester between a carboxyl of the amino acid and a hydroxyl of polyethylene glycol, or indirectly, e.g., by reacting polyethylene glycol with epichlorohydrin to form an epoxypropyl ether and reacting the resulting epoxide with the amino group of the amino acid to covalently bond the amino acid and polyethylene glycol via a 2-hydroxypropyl linker. Various moieties and reactions that directly or indirectly link various moieties are well known in the art. In certain preferred embodiments, unless otherwise indicated by the context, the indirect bond simply contains 1-10 intervening atoms (e.g., methylene, dibutyl ether, tripeptide, etc.), most preferably 1-6 intervening atoms.

[0243] As used herein, a therapeutic agent that "prevents" a disorder or condition refers to one that, in a statistical sample, reduces the occurrence of the disorder or condition in a treated sample compared to an untreated control sample, or reduces the severity or delays the onset of one or more symptoms of the disorder or condition compared to an untreated control sample.

[0244] The term "treating" includes prophylactic and / or therapeutic treatments. The term "prophylactic or therapeutic" treatments are known in the art and include administering one or more of the compositions of the present invention to a host. When administered before clinical symptoms of an undesired condition (e.g., a disease or other undesired condition of a host animal) appear, the treatment is prophylactic (i.e., protects the host from developing the undesired condition), whereas when administered after symptoms of the undesired condition appear, the treatment is therapeutic (i.e., intended to reduce, alleviate, or stabilize an existing undesired condition or its side effects).

[0245] The terminology "prodrug" is intended to include compounds that are converted to the therapeutically active agent of the present invention under physiological conditions. The usual method of making prodrugs is to include one or more selected moieties that are hydrolyzed under physiological conditions to expose the target molecule. In other embodiments, the prodrug is converted by the enzyme activity of the host animal. For example, esters or carbonates (e.g., esters or carbonates of alcohols or carboxylic acids) are suitable prodrugs.

[0246] Hereinafter, the configuration of the embodiment will be described in detail by way of examples. However, the following examples are merely intended to aid in the understanding of the present invention and are not intended to limit the scope of the present invention.

[0247] [Example] In one embodiment of the present invention, the linker-drug compounds and linker-drug-ligand conjugates of the present invention may be synthesized according to the following process.

[0248] [Linker-Drug synthesis route] 1) Synthesis of the linker [ka]

[0249] 2) Linker-drug synthesis [ka]

[0250] [Synthetic pathway for linker-drug-ligand conjugates] The linker-drug-ligand conjugates of the present invention may be prepared using the techniques provided herein and the knowledge of those skilled in the art.

[0251] For example, linkers are described in PCT / US2016 / 063564 and PCT / US2016 / 063595, which are incorporated by reference in their entirety into this specification, and which are incorporated by reference into this specification even if not described herein, or can be made by one skilled in the art following known references.

[0252] Example 1: Preparation of Compound 5 [ka]

[0253] Preparation of compound 1 Under a nitrogen atmosphere, 2-(2-(2-chloroethoxy)ethoxy)ethanol (10.0 g, 59.3 mmol) was dissolved in acetone (60 mL), and then sodium iodide (26.0 g, 177.9 mmol) was added and the mixture was refluxed for 12 hours. After the reaction was completed, the mixture was concentrated under reduced pressure and used for column chromatography to obtain compound 1 (13.0 g, 85%). 1 H-NMR(400 MHz, CDCl3)δ 3.79-3.73(m,4H),3.70-3.68(m,4H),3.64-3.62(m,2H),3.29-3.25(m,2H).

[0254] Preparation of compound 2 Compound 1 (13.0 g, 49.9 mmol) was dissolved in acetone (316 mL) at 0°C under a nitrogen atmosphere, and then Jones reagent (31.6 mL) was added and stirred at room temperature for 15 hours. After the reaction was completed, ethyl acetate (2 x 100 mL) and distilled water (150 mL) were added, and the extracted organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Compound 2 (13.1 g, 96%) was obtained by purification using column chromatography. 1 H-NMR(400 MHz, CDCl3)δ 4.22(s,2H),3.80-3.66(m,6H),3.29-3.25(m,2H).

[0255] Preparation of compound 3 Compound 2 (13.1 g, 47.9 mmol) was dissolved in methanol (121 mL) at 0° C. under a nitrogen atmosphere, and then oxalyl chloride (6.1 mL, 71.9 mmol) was added and stirred at room temperature for 16 hours. After the reaction was completed, the mixture was concentrated under reduced pressure and purified by column chromatography to obtain compound 3 (9.8 g, 71%). 1 H-NMR(400 MHz, CDCl3)δ 4.19(s,2H),3.78-3.70(m,9H),3.27(t,J=7.0Hz,2H).

[0256] Preparation of compound 4 Compound 3 (9.75 g, 33.8 mmol) was dissolved in N,N-dimethylformamide (143 mL), and N,N-dihydroxylamine (10.3 g, 44.0 mmol) and sodium hydride (60% in oil, 1.63 g, 40.6 mmol) were added at 0°C under a nitrogen atmosphere. The reaction solution was stirred for 15 hours, and then extracted with distilled water (200 mL) and ethyl acetate (3 x 150 mL). The organic layer was dried over anhydrous sodium sulfate. After filtration, the mixture was concentrated under reduced pressure and purified by column chromatography to obtain compound 4 (10.6 g, 80%). 1H-NMR(400 MHz, CDCl3)δ 4.17(s,2H),4.09(t,J=7.0Hz,2H),3.76-3.73(m,9H),1.54(s,18H).

[0257] Preparation of compound 5 Compound 4 (10.6 g, 26.9 mmol) was dissolved in tetrahydrofuran / methanol / distilled water (240 mL / 80 mL / 80 mL), and sodium hydroxide (2.7 g, 40.4 mmol) was added at 0° C. under a nitrogen atmosphere. The reaction temperature was raised to room temperature, and the mixture was stirred for 3 hours. The pH of the reaction solution was adjusted to 4 using 1N aqueous hydrochloric acid, and then distilled water (100 mL) and ethyl acetate (2×100 mL) were added for extraction, and the combined organic layer was dried over anhydrous sodium sulfate. Compound 5 (6.76 g, 90%) was obtained by filtration and concentration under reduced pressure, and was used in the next reaction without further purification. 1 H-NMR(400 MHz, CDCl3)δ 4.15(s,2H),4.05-4.03(m,2H),3.77-3.69(m,6H),1.48(s,9H).

[0258] Example 2: Preparation of Compound 8 [ka]

[0259] Preparation of compound 6 2-Amino-2-(hydroxymethyl)-1,3-propanediol (Tris, 5 g, 41.3 mmol) and thionyl chloride (30.0 mL, 413 mmol) were added under nitrogen atmosphere at 0°C, and the mixture was stirred in suspension. Pyridine (4.9 mL, 20.6 mmol) was gradually added to the mixture at -30°C, and when gas began to be generated during the reaction, the temperature was raised to 120°C and stirred for 2 hours. The reaction solution was cooled to 0°C, and distilled water (5 mL) was gradually added for 10 minutes, and then a solution of sulfuric acid (3 mL, 0.04 mmol) diluted with distilled water (5 mL) was added and stirred. After extraction with dichloromethane (2 x 300 mL) and 30% aqueous sodium hydroxide solution (100 mL), the combined organic layer was dried over anhydrous sodium sulfate. After filtration, the mixture was concentrated under reduced pressure, and diethyl ether (100 mL) and hydrochloric acid (2 M in Et2O, 23 mL) were added. The resulting solid was filtered to give compound 6 (4.6 g, 63%). 1 H-NMR(400 MHz,DMSO-d6)δ 9.06(s,2H),4.00(s,6H).

[0260] Preparation of compound 7 Compound 6 (2.6 g, 14.74 mmol) and sodium azide (4.8 g, 73.5 mmol) were dissolved in distilled water (63 mL) and stirred at 100° C. for 15 hours. The reaction solution was concentrated under reduced pressure, diluted with distilled water (60 mL), and extracted with diethyl ether (6×100 mL). The combined organic layer was dried over anhydrous sodium sulfate. Compound 7 (1.3 g, 45%) obtained by filtration and concentration was used in the next reaction without further purification. 1 H-NMR(400 MHz,CDCl3)δ 3.34(s,6H). 1 H-NMR (400 MHz, DMSO-d6)9.06(s,2H),4.00(s,6H).

[0261] Preparation of compound 8 Compound 5 (1g, 3.58mmol) and compound 7 (773mg, 3.94mmol) were dissolved in N,N-dimethylformamide (15mL), and then N,N-diisopropylethylamine (1.3mL, 7.16mmol) and N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (1.5g, 3.93mmol) were added under nitrogen atmosphere. The reaction solution was stirred at room temperature for 14 hours, concentrated under reduced pressure, and purified by column chromatography to obtain compound 8 (600mg, 37%). 1 H-NMR(400 MHz, CDCl3)δ 7.39(s,1H),6.87(s,1H),4.07(t,J=4.6Hz,2H),3.96(s,2H),3.72(s,6H),3.70-3.77(m,6H),1.48(s,9H).

[0262] Example 3: Preparation of Compound 14 [ka]

[0263] Preparation of compound 9 2-Amino-2-(hydroxymethyl)-1,3-propanediol (Tris, 5.0 g, 41.3 mmol) was dissolved in dimethyl sulfoxide (8 mL), and then 5N aqueous sodium hydroxide solution (0.8 mL) was added under a nitrogen atmosphere, followed by gradual addition of t-butyl acrylate (21.0 mL, 140 mmol). The reaction solution was stirred at room temperature for 16 hours, after which distilled water (100 mL) was added to the reaction solution and extracted with ethyl acetate (2 x 100 mL). The combined organic layer was dried over anhydrous sodium sulfate. After filtration, the mixture was concentrated and purified by column chromatography to obtain compound 9 (9.05 g, 44%). 1 H-NMR(400 MHz, CDCl3)δ 3.64(t,J=6.2Hz,6H),3.31(s,6H),2.45(t,J=6.2Hz,6H),1.45(s,27H).

[0264] Preparation of compound 10 Compound 9 (9.05 g, 17.9 mmol) was dissolved in tetrahydrofuran (170 mL), and lithium aluminum hydride (1 M in THF, 54 mL) was added at 0° C. under a nitrogen atmosphere. The reaction solution was stirred at room temperature for 4 hours, and then distilled water (2 mL), 15% w / w aqueous sodium hydroxide solution (2 mL), and distilled water (6 mL) were added in this order. After drying with anhydrous sodium sulfate, filtration and concentration were performed to obtain compound 10 (4.3 g, 82%), which was used in the next reaction without further purification. 1 H―NMR(400 MHz, CDCl3)δ 3.75(t,J=5.4Hz,6H),6.22(t,J=5.4Hz,6H),3.36(s,6H),1.83―1.78(m,6H).

[0265] Preparation of compound 11 Compound 10 (4.3 g, 14.6 mmol) was dissolved in methanol (50 mL), and then a solution of di-t-butyl dicarbonate (3.3 g, 15.1 mmol) in methanol (25 mL) was slowly added under a nitrogen atmosphere at 0° C. The reaction solution was stirred at room temperature for 12 hours, concentrated under reduced pressure, and purified by column chromatography to obtain compound 11 (4.05 g, 70%). 1 H―NMR(400 MHz, CDCl3)δ 3.73(t,J=5.2Hz,6H),3.67(s,6H),3.61(t,J=5.2Hz,6H),1.81―1.78(m,6H).

[0266] Preparation of compound 12 Compound 11 (1 g, 2.52 mmol) was dissolved in tetrahydrofuran (8 mL), and then 4-methylmorpholine (1.2 mL, 11.5 mmol) and methanesulfonic anhydride (2 g, 11.5 mmol) were added at 0°C under nitrogen atmosphere. The reaction solution was stirred for 2 hours, concentrated under reduced pressure, dissolved in N,N-dimethylformamide (9 mL), and sodium azide (850 mg, 12.8 mmol) was added. The reaction solution was stirred at 100°C for 2 hours, cooled to room temperature, and saturated aqueous ammonium chloride solution (8 mL) was added, followed by extraction with ethyl acetate (2 x 30 mL). The combined organic layer was wiped with brine (2 x 30 mL) and dried over anhydrous sodium sulfate. After filtration, the mixture was concentrated and purified by column chromatography to obtain compound 12 (984 mg, 82%). 1 H-NMR(400 MHz, CDCl3)δ 3.64(s,6H),3.51(t,J=5.8Hz,6H),3.36(t,J=6.6Hz,6H),1.86-1.80(m,6H),1.43(s,9H).

[0267] Preparation of compound 13 Compound 12 (167 mg, 0.34 mmol) was dissolved in dichloromethane (4 mL), and hydrochloric acid (4N in 1,4-dioxane, 1 mL, 10 mmol) was added under a nitrogen atmosphere at 0° C. The reaction solution was stirred at room temperature for 12 hours and then concentrated under reduced pressure to give compound 13 (131 mg, 99%). 1 H―NMR(400 MHz, CDCl3)δ 8.37(s,2H),3.70(s,6H),3.60(t,J=5.4Hz,6H),3.47(t,J=6.6Hz,6H),1.90―1.87(m,6H).

[0268] Preparation of compound 14 Compound 13 (148 mg, 0.4 mmol) and compound 5 (313 mg, 1.12 mmol) were dissolved in N,N-dimethylformamide (1.6 mL), and then N,N-diisopropylethylamine (0.15 mL, 1.68 mmol) and N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (410 mg, 1.08 mmol) were added in this order at 0°C under a nitrogen atmosphere. The reaction solution was stirred at room temperature for 14 hours, concentrated under reduced pressure, and purified by column chromatography to obtain compound 14 (130 mg, 50%). 1 H-NMR(400 MHz, CDCl3)δ 7.51(s,1H),6.79(s,1H),4.03(t,J=4.4Hz,2H),3.92(s,2H),3.72(s,6H),3.70-6.79 (m,6H),3.52(t,J=5.6Hz,6H),3.65(t,J=6.6Hz,6H),1.86-1.80(m,6H),1.48(s,9H).

[0269] Example 4: Preparation of Compound 18 [ka]

[0270] Preparation of compound 15 Hexaethylene glycol (50.0 g, 177 mmol), silver oxide (61.6 g, 266 mmol), and potassium iodide (5.85 g, 35.4 mmol) were diluted with dichloromethane (500 mL) and then sonicated for 15 minutes. A solution of 4-toluenesulfonyl chloride (34.4 g, 181 mmol) dissolved in dichloromethane (100 mL) was slowly added to this solution at -30°C. The reaction solution was gradually warmed to 0°C and held for 15 minutes, then dried over anhydrous sodium sulfate. After filtration, the mixture was concentrated and purified by column chromatography to obtain compound 15 (61.46 g, 80%). 1H-NMR(400 MHz, CDCl3)δ 7.80(d,J=8.0Hz,2H),7.35(d,J=8.0Hz,2H),4.16(m,2H),3.71-3.58(m,22H),2.45(s,3H).

[0271] Preparation of compound 16 Compound 15 (5 g, 11.5 mmol) and sodium azide (1.2 g, 17.2 mmol) were dissolved in N,N-dimethylformamide (30 mL) and stirred at 100° C. for 15 hours. After filtration, the mixture was concentrated and purified by column chromatography to obtain compound 16 (3.16 g, 90%). 1 H-NMR (400 MHz, CDCl3) δ 3.72-3.66 (m, 20H), 3.62-3.60 (m, 2H), 3.39 (t, J=5.0Hz, 2H), 2.88 (brs, 1H).

[0272] Preparation of compound 17 Compound 16 (3.16 g, 10.3 mmol) was dissolved in N,N-dimethylformamide (21 mL), and sodium hydride (55% in oil, 494 mg, 12.3 mmol) was added at 0°C under nitrogen atmosphere. After 30 minutes, propargyl bromide (1.2 mL, 13.4 mmol) was added at 0°C under nitrogen atmosphere. The reaction solution was stirred at room temperature for 1 hour, and then distilled water (20 mL) was added to the reaction solution, followed by extraction with ethyl acetate (2 x 20 mL). The combined organic layer was wiped with saturated aqueous ammonium chloride solution (10 mL) and brine (20 mL), and then dried over anhydrous sodium sulfate. After filtration, the mixture was concentrated and purified by column chromatography to obtain compound 17 (3.05 g, 86%). 1 H―NMR(400 MHz, CDCl3)δ 4.20(s,2H),3.69―3.66(m,22H),3.39(t,J=5.0Hz,2H),2.43(s,1H).

[0273] Preparation of compound 18 Compound 17 (3.05 g, 8.83 mmol) was dissolved in tetrahydrofuran (35 mL), and triphenylphosphine (2.80 g, 10.6 mmol) was added. The reaction solution was stirred at room temperature for 1 hour, and distilled water (3.2 mL, 177 mmol) was added. The reaction solution was heated to reflux and stirred for 18 hours. The reaction solution was cooled to room temperature, concentrated, and purified by column chromatography to obtain compound 18 (2.60 g, 92%). 1 H―NMR(400 MHz, CDCl3)δ 4.21(s,2H),3.71―3.64(m,20H),3.51(t,J=5.0Hz,2H),2.87(t,J=5.0Hz,2H),2.43(s,1H).

[0274] Example 5: Preparation of Compound 21 [ka]

[0275] Preparation of compound 20 Compound 19 (2.82 g, 5.82 mmol, compound 19 was prepared by the method described in Patent Document 16) was dissolved in N,N-dimethylformamide (15 mL), and then compound 18 (2.05 g, 6.4 mmol), N,N-diisopropylethylamine (2.1 mL, 11.6 mmol), and N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (2.65 g, 6.98 mmol) were added at 0°C under a nitrogen atmosphere. The reaction solution was stirred at 0°C for 30 minutes and then stirred at room temperature for 1 hour. Distilled water (50 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (2 x 50 mL). The combined organic layer was dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and purified by column chromatography to obtain compound 20 (3.04 g, 67%). 1H-NMR(400 MHz, CDCl3)δ 7.46-7.42(m,2H),7.05(d,J=8.8Hz,1H),5.39-5.26(m,4H),4.65(s,2H),4. 23-4.20(m,3H),3.74(s,3H),3.69-3.62(m,24H),2.45(s,1H),2.06(s,9H).

[0276] Preparation of compound 21 Compound 20 (3.04 g, 3.9 mmol) was dissolved in dichloromethane (40 mL), and then bis(4-nitrophenyl)carbonate (1.42 g, 4.64 mmol) and N,N-diisopropylethylamine (1.1 mL, 5.85 mmol) were added at 0°C under nitrogen atmosphere. The reaction solution was stirred at 0°C for 30 minutes and then at room temperature for 2 hours. Distilled water (30 mL) was added to the reaction solution, and the mixture was extracted with dichloromethane (30 mL). The combined organic layer was wiped with saline and dried over anhydrous sodium sulfate. After filtration, the mixture was concentrated under reduced pressure and purified by column chromatography to obtain compound 21 (3.1 g, 84%). 1 H-NMR(400 MHz, CDCl3)δ 8.28(d,J=8.4Hz,2H),8.14(s,1H),7.54(d,J=8.0Hz2H),7.38(d,J=8.0Hz,2H),7.09(d,J=8.4Hz,1H),5.4 1―5.31(m,4H),5.27(s,2H),4.24―4.22(m,3H),3.74(s,3H).3.69―3.64(m,24H),2.44(s,1H),2.06(s,9H).

[0277] Example 6: Preparation of Compound 27 [ka]

[0278] Preparation of compound 22 1-Benzyl N-(t-butoxycarbonyl)-D-glutamic acid (3.0 g, 8.89 mmol) was dissolved in N,N-dimethylformamide (30 mL), and N,N-diisopropylethylamine (1.86 mL, 10.67 mmol) and iodomethane (0.66 mL, 10.67 mmol) were added. The reaction solution was stirred at room temperature for 2 hours, and then distilled water (50 mL) was added and extracted with ethyl acetate (50 mL). The combined organic layer was dried over anhydrous sodium sulfate. After filtration, the mixture was concentrated under reduced pressure and purified by column chromatography to obtain compound 22 (2.05 g, 66%). 1 H-NMR(400 MHz, CDCl3)δ 7.35(s,5H),5.20(s,1H),5.13-5.11(m,1H),4.38-4.37(m,1H),3.65(s,3H),2.45-2.30(m,2H),1.98-1.93(m,1H),1.58(s,9H).

[0279] Preparation of compound 23 Compound 22 (2.05 g, 5.83 mmol) and palladium / charcoal (10% w / w, 200 mg) were dissolved in methanol (30 mL), and the reaction solution was stirred at room temperature under a hydrogen atmosphere for 1 hour. The reaction solution was filtered through Celite and concentrated under reduced pressure to obtain compound 23 (1.5 g, 99%). 1 H-NMR(400 MHz, CDCl3)δ 5.20-5.18(m,1H),4.34-4.24(m,1H),3.73(s,1H),2.52-2.42(m,2H),2.62-2.23(m,1H),2.04-2.00(m,1H),1.48(s,9H).

[0280] Preparation of compound 24 Compound 23 (730 mg, 2.80 mmol) and propargylamine (0.22 mL, 3.35 mmol) were dissolved in N,N-dimethylformamide (20 mL), and then N,N-diisopropylethylamine (0.97 mL, 5.58 mmol), 1-hydroxybenzotriazole (453 mg, 3.35 mmol), and N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (642 mg, 3.35 mmol) were added. The reaction solution was stirred at room temperature for 14 hours, and then distilled water (30 mL) was added and extracted with ethyl acetate (3 x 30 mL). The combined organic layer was wiped with 0.5 N aqueous hydrochloric acid (30 mL), saturated aqueous ammonium chloride (30 mL), and saline (30 mL) in this order, and then dried over anhydrous sodium sulfate. After filtration, the mixture was concentrated under reduced pressure and purified by column chromatography to obtain compound 24 (700 mg, 84%). 1 H-NMR(400 MHz, CDCl3)δ 6.76(s,1H),5.33(s,1H),4.17(s,1H),4.05―4.04(m,2H),3.69(s,3H),2.53―2. 23(m,2H),2.26-2.19(m,1H),2.17-2.13(m,1H),1.98-1.89(m,1H),1.44(s,9H).

[0281] Preparation of compound 25 Compound 24 (700 mg, 2.35 mmol) was dissolved in dichloromethane (10 mL), and hydrochloric acid (4N in 1,4-dioxane, 5 mL) was added under a nitrogen atmosphere at 0° C. The reaction solution was stirred at room temperature for 2 hours, and then concentrated under reduced pressure to give compound 25 (549 mg, 100%). 1 H-NMR(400 MHz, CDCl3)δ 10.23(s,3H),4.47-4.09(m,1H),3.99-3.84(m,2H),3.69(s,3H),2.67-2.64(m,2H),2.42-2.28(m,3H).

[0282] Preparation of compound 26 Compound 25 (653 mg, 2.79 mmol) and compound 19 (1.23 g, 2.54 mmol) were dissolved in N,N-dimethylformamide (20 mL), and then N,N-diisopropylethylamine (1.33 mL, 7.62 mmol) and N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (1.16 g, 3.05 mmol) were added. The reaction solution was stirred at room temperature for 14 hours, and then distilled water (50 mL) was added and extracted with ethyl acetate (3 x 50 mL). The combined organic layer was wiped with saturated aqueous sodium bicarbonate solution (30 mL) and brine (30 mL), and then dried over anhydrous sodium sulfate. After filtration, the mixture was concentrated and purified by column chromatography to obtain compound 26 (1.36 g, 82%). 1 H-NMR(400 MHz, CDCl3)δ 7.94(s,1H),7.74(d,J=8.0Hz,1H),7.52(dd,J=2.2,10.4Hz,1H),7.05(d,J=8.4Hz,1H),6.85(m,1H),5.43−5.33(m,4H),4.73−4. 69(m,3H),4.15-4.09(m,3H),3.69(d,J=7.6Hz,6H),2.56-2.51(m,2H),2.40-2.35(m,1H),2.06(t,J=9.6Hz),1.89-1.86(m,1H).

[0283] Preparation of compound 27 Compound 26 (500 mg, 0.75 mmol) was dissolved in N,N-dimethylformamide (20 mL), and then bis(4-nitrophenyl)carbonate (229 mg, 0.75 mmol) and N,N-diisopropylethylamine (0.2 mL, 1.13 mmol) were added at 0°C under a nitrogen atmosphere. The reaction solution was stirred at room temperature for 12 hours, and then distilled water (50 mL) was added to the reaction solution. After extraction with ethyl acetate (2 x 50 mL), the combined organic layer was dried over anhydrous sodium sulfate. After filtration, the mixture was concentrated and purified by column chromatography to obtain compound 27 (518 mg, 83%). 1H-NMR(400 MHz, CDCl3)δ 8.27(d,J=8.8Hz,2H),8.09(s,1H),7.78(d,J=8.8Hz,1H),7.58(dd,J=2.2,10.4Hz, 1H),7.38(d,J=9.2Hz,1H),7.10(d,J=8.4Hz,1H),6.80(m,1H),5.45-5.39(m,4H),5 .27(s,2H),4.73-4.69(m,1H),4.18-4.09(m,3H),3.69(d,J=6.8Hz,6H),2.53-2.51 (m,2H),2.42-2.27(m,1H),2.26-2.23(m,1H),2.21-2.15(m,2H),2.05(t,J=9.6Hz).

[0284] Example 7: Preparation of Compound 29 [ka]

[0285] Preparation of compound 28 Compound 27 (198 mg, 0.24 mmol) was dissolved in N,N-dimethylformamide (1 mL), and monomethyl auristatin E (150 mg, 0.22 mmol) was added at room temperature under a nitrogen atmosphere. 1-Hydroxy-7-azabenzotriazole (6 mg, 0.043 mmol), pyridine (0.2 mL), and N,N-diisopropylethylamine (0.076 mL, 0.44 mmol) were added to the reaction solution. The reaction solution was stirred at room temperature for 24 hours, concentrated under reduced pressure, and purified by column chromatography to obtain compound 28 (258 mg, 76%). EI―MSm / z:1 / 2[M+H]+1502.7,[M+H]+1409.2.

[0286] Preparation of compound 29 Compound 28 (258 mg, 0.18 mmol) was dissolved in tetrahydrofuran / methanol (2 mL / 2 mL), and then a solution of lithium hydroxide (38 mg, 0.92 mmol) in distilled water (2 mL) was gradually added at -40°C. The reaction temperature was gradually raised to 0°C while stirring for 2 hours. The pH of the reaction solution was adjusted to about 4-5 with acetic acid, and the reaction solution was concentrated under reduced pressure. The residue was dissolved in acetonitrile / distilled water (1 mL / 1 mL), purified by HPLC, and lyophilized to obtain compound 29 as a white solid (159 mg, 69%). EI―MSm / z:[M+H]+1255.0,[M+Na]+1277.0.

[0287] Example 8: Preparation of Compound 34 [ka]

[0288] Preparation of compound 31 Compound 30 (4.5 g, 25.7 mmol, compound 30 was prepared by the method described in Patent Document 16) was dissolved in N,N-dimethylformamide (50 mL), and then propargyl bromide (~80% in toluene, 4.96 mL, 33.4 mmol) and sodium hydride (60% in oil, 1.23 g, 30.8 mmol) were added at 0°C under a nitrogen atmosphere. The reaction solution was stirred at room temperature for 3 hours, and then distilled water (50 mL) was added and extracted with ethyl acetate (50 mL). The combined organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure, and then purified by column chromatography to obtain compound 31 (4.35 g, 79%). 1 H―NMR(400 MHz, CDCl3)δ 4.21(d,J=2.4Hz,2H),3.70―3.67(m,10H),3.39(d,J=5.2Hz,2H),2.43(t,J=2.4Hz,1H).

[0289] Preparation of compound 32 Compound 31 (2.7 g, 7.23 mmol) was dissolved in tetrahydrofuran / distilled water (30 mL / 1.5 mL), and triphenylphosphine (2.09 g, 7.97 mmol) was added. The reaction solution was stirred at room temperature for 24 hours, concentrated under reduced pressure, and purified by column chromatography to obtain compound 32 (1.32 g, 99%). 1 H-NMR(400 MHz, CDCl3)δ 4.21(s,2H),3.69-3.64(m,8H),3.53-3.50(m,2H),2.88-2.85(m,2H),2.43(s,1H). EI―MSm / z:[M+H]+188.2,[M+Na]+210.3.

[0290] Preparation of compound 33 Compound 23 (888 mg, 3.40 mmol) and compound 32 (700 mg, 3.74 mmol) were dissolved in N,N-dimethylformamide (30 mL), and then N,N-diisopropylethylamine (1.18 mL, 6.80 mmol), 1-hydroxybenzotriazole (551 mg, 4.08 mmol), and N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (782 mg, 4.08 mmol) were added at 0°C under a nitrogen atmosphere. The reaction solution was stirred at room temperature for 14 hours, and then distilled water (30 mL) was added and extracted with ethyl acetate (3 x 30 mL). The combined organic layer was wiped with 0.5N hydrochloric acid aqueous solution (30 mL), saturated sodium bicarbonate aqueous solution (30 mL), and brine (30 mL) in this order, and then dried over anhydrous sodium sulfate. After filtration, the mixture was concentrated and purified by column chromatography to give compound 33 (1.23 g, 84%). 1 H-NMR(400 MHz, CDCl3)δ 4.22(s,2H),4.21(br,1H),3.72-3.58(m,10H),3.57-3.55(m,2H),3.48-3.44 (m,2H),2.48-2.39(m,3H),2.17-2.11(m,2H),1.96-1.88(m,2H),1.43(s,9H).

[0291] Preparation of compound 34 Compound 33 (770 mg, 1.79 mmol) was dissolved in dichloromethane (10 mL), and hydrochloric acid (4N in 1,4-dioxane, 5 mL) was added under a nitrogen atmosphere at 0° C. The reaction solution was stirred at room temperature for 1 hour and then concentrated under reduced pressure to give compound 34 (656 mg, 100%). EI―MSm / z:[M+H]+331.3,[M+Na]+353.3.

[0292] Example 9: Preparation of Compound 37 [ka]

[0293] Preparation of compound 36 Compound 35 (150 mg, 0.122 mmol, compound 35 was prepared by the method described in Patent Document 16) and compound 34 (47 mg, 0.128 mmol) were dissolved in N,N-dimethylformamide (2 mL), and then N,N-diisopropylethylamine (0.053 mL, 0.305 mmol) and N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (56 mg, 0.146 mmol) were added at 0°C under a nitrogen atmosphere. The reaction solution was stirred at room temperature for 22 hours, concentrated under reduced pressure, and purified by column chromatography to obtain compound 36 (150 mg, 80%). EI―MSm / z:1 / 2[M+H]+771.6,[M+H]+1541.4,[M+Na]+1563.4.

[0294] Preparation of compound 37 Compound 36 (150 mg, 0.097 mmol) was dissolved in tetrahydrofuran / methanol (2 mL / 2 mL), and then a solution of lithium hydroxide (38 mg, 0.584 mmol) in distilled water (2 mL) was gradually added at -40°C. The reaction temperature was gradually raised to 0°C while stirring for 2 hours. The pH of the reaction solution was adjusted to about 4-5 with acetic acid, then diluted with acetonitrile / distilled water (1 mL / 1 mL), purified by HPLC, and lyophilized to obtain compound 37 as a white solid (100 mg, 74%). EI―MSm / z:1 / 2[M+H]+694.4,[M+H]+1387.2,[M+Na]+1409.2.

[0295] Example 10: Preparation of Compound 39 [ka]

[0296] Preparation of compound 38 Compound 29 (61 mg, 0.05 mmol) and compound 8 (5 mg, 0.014 mmol) were dissolved in ethanol / dichloromethane (1 mL) and distilled water (1 mL), and then copper sulfate (1.7 mg, 0.007 mmol) and sodium ascorbate (1.7 mg, 0.007 mmol) were added at 0° C. under a nitrogen atmosphere. The reaction solution was stirred at room temperature for 1 hour, and the reaction solvent was evaporated with nitrogen gas, diluted with dimethyl sulfoxide (1 mL), purified by HPLC, and lyophilized to obtain compound 38 (40.0 mg, 70%) as a white solid. EI―MSm / z:1 / 2[M+H]+2111.9,1 / 3[M+H]+1408.3,1 / 4[M+H]+1056.5.

[0297] Preparation of compound 39 Compound 38 (28 mg, 6.0 μmol) was dissolved in dichloromethane (1 mL), trifluoroacetic acid (0.4 mL) was added at 0° C., and the mixture was stirred for 1 hour. The reaction solution was concentrated under reduced pressure, purified by HPLC, and lyophilized to obtain compound 39 as a white solid (10 mg, 40%). EI―MSm / z:1 / 2[M+H]+2061.3,1 / 3[M+H]+1374.9,1 / 4[M+H]+1031.4.

[0298] Example 11: Preparation of Compound 41 [ka]

[0299] Preparation of compound 40 Compound 37 (68 mg, 0.049 mmol) and compound 8 (5 mg, 0.014 mmol) were dissolved in ethanol / dichloromethane (1 mL) and distilled water (1 mL), and then copper sulfate (1.7 mg, 7 μmol) and sodium ascorbate (3.0 mg, 0.014 mmol) were added at 0° C. under a nitrogen atmosphere. The reaction solution was stirred at room temperature for 1 hour, and the reaction solvent was evaporated with nitrogen gas, diluted with dimethyl sulfoxide (1 mL), purified by HPLC, and lyophilized to obtain compound 40 as a white solid (28 mg, 37%). EI―MSm / z:1 / 2[M+H]+2309.8,1 / 3[M+H]+1540.4,1 / 4[M+H]+1155.6.

[0300] Preparation of compound 41 Compound 40 (28 mg, 6.0 μmol) was dissolved in dichloromethane (1 mL), and trifluoroacetic acid (0.4 mL) was added at 0° C. and stirred for 3 hours. The reaction solution was concentrated under reduced pressure, purified by HPLC, and lyophilized to obtain compound 41 as a white solid (5 mg, 20%). EI―MSm / z:1 / 2[M+H]+2260.4,1 / 3[M+H]+1507.6,1 / 4[M+H]+1130.6.

[0301] Example 12: Preparation of Compound 47 [ka]

[0302] Preparation of compound 42 3-Aminopentanedione hydrochloride (5.0 g, 27.2 mmol) was dissolved in distilled water / 1,4-dioxane (6 mL / 44 mL), and then aqueous sodium hydroxide (4 M, 20.4 mL, 81.6 mmol) and di-t-butyl dicarbonate (6.87 mL, 29.9 mmol) were added. The reaction solution was stirred at room temperature for 15 hours, and the pH was adjusted to about 2 with 5% aqueous potassium hydrogen sulfate, and extracted with ethyl acetate (3 x 50 mL). The combined organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to give compound 42 (4.0 g, 60%). 1 H―NMR(400 MHz,CD3OD)δ 4.25(t,J=6.2Hz,1H),2.56(d,J=5.6Hz,4H),1.43(s,9H).EI―MSm / z:[M+Na]+270.3.

[0303] Preparation of compound 44 Compound 42 (3.04 g, 12.3 mmol) and compound 43 (4.28 g, 24.6 mmol, compound 43 was prepared according to the method described in J. Am. Chem. Soc. 2016, 138, 3382-3394) were dissolved in N,N-dimethylformamide (25 mL), and then N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (7.02 g, 18.45 mmol) and N,N-diisopropylethylamine (4.28 mL, 24.6 mmol) were added at 0°C under a nitrogen atmosphere. The reaction solution was stirred at room temperature for 6 hours, and then saturated aqueous ammonium chloride solution (50 mL) was added to the reaction solution and extracted with ethyl acetate (2 x 50 mL). The combined organic layer was wiped with brine (30 mL) and dried over anhydrous sodium sulfate. After filtration, the mixture was concentrated and purified by column chromatography to give compound 44 (3.93 g, 57%). 1 H-NMR(400 MHz, CDCl3)δ 6.84(s,2H),6.06(s,1H),4.17(m,1H),3.66-3.61(m,16H),3.45-3.39(m,8H),2.60-2.56(m,2H),2.37-2.32(m,2H),1.43(s,9H).

[0304] Preparation of compound 45 Compound 44 (3.93 g, 7.02 mmol) was dissolved in dichloromethane (12 mL), and hydrochloric acid (4 M in 1,4-dioxane, 12.3 mL, 49.1 mmol) was added under a nitrogen atmosphere at 0° C. The reaction solution was stirred at room temperature for 1 hour, and then concentrated under reduced pressure to obtain compound 45 (crude, 3.5 g). 1 H-NMR(400 MHz,CDCl3)δ 8.45(s,2H),7.41(s,1H),3.97(m,1H),3.66-3.43(m,24H),3.29-2.93(m,2H),2.76-2.73(m,2H). EI-MS m / z: [M+H]+460.5.

[0305] Preparation of compound 46 Compound 45 (crude 3.5 g) and compound 5 (2.24 g, 8.0 mmol) were dissolved in N,N-dimethylformamide (18 mL), and then N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (3.21 g, 8.44 mmol) and N,N-diisopropylethylamine (2.44 mL, 14.04 mmol) were added at 0 °C under nitrogen atmosphere. The reaction solution was stirred at room temperature for 15 hours, and then saturated aqueous ammonium chloride solution (50 mL) was added to the reaction solution, followed by extraction with ethyl acetate (2 × 50 mL). The combined organic layer was wiped with brine (30 mL) and dried over anhydrous sodium sulfate. After filtration, the mixture was concentrated and purified by column chromatography to obtain compound 46 (3.97 g, 2 steps 79%). 1 H-NMR(400 MHz, CDCl3)δ 8.45(s,1H),7.88(d,J=7.2Hz,1H),6.79(s,2H),4.56(m,1H),4.07-3.97(m,4H),3.75 -3.58(m,22H),3.44-3.39(m,8H),2.63-2.60(m,2H),2.44-2.40(m,2H),1.47(s,9H). EI-MS m / z: [M+H]+721.7.

[0306] Preparation of compound 47 Compound 46 (370 mg, 0.51 mmol) was dissolved in tetrahydrofuran (5 mL), and triphenylphosphine (296 mg, 1.13 mmol) and distilled water (0.18 mL) were added. The reaction solution was heated to reflux and stirred for 4 hours. Compound 47 (316 mg, 92%) was obtained by purification using column chromatography. 1 H-NMR(400 MHz,CDCl3)δ 4.57(m,1H),4.07-3.97(m,4H),3.75-3.42(m,30H),3.01(m,2H),2.57(m,2H),1.47(s,9H). EI-MS m / z: [M+H]+669.8.

[0307] Example 13: Preparation of Compound 50 [ka]

[0308] Preparation of compound 48 Compound 47 (37 mg, 0.055 mmol) and compound 35 (143 mg, 0.116 mmol) were dissolved in N,N-dimethylformamide (2 mL), and then N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (43.9 mg, 0.111 mmol) and N,N-diisopropylethylamine (0.04 mL, 0.221 mmol) were added at 0°C under nitrogen atmosphere. The reaction solution was stirred at room temperature for 72 hours, and then saturated aqueous ammonium chloride solution (20 mL) was added to the reaction solution and extracted with ethyl acetate (2 x 20 mL). The combined organic layer was wiped with brine (10 mL) and dried over anhydrous sodium sulfate. After filtration, the mixture was concentrated and purified by column chromatography to obtain compound 48 (95 mg, 56%). EI―MSm / z:1 / 2[M+H]+1546.1,1 / 3[M+H]+1031.1.

[0309] Preparation of compound 49 Compound 48 (95 mg, 0.031 mmol) was dissolved in methanol / tetrahydrofuran (0.8 mL / 1.6 mL), and then a solution of lithium hydroxide (12.9 mg, 0.31 mmol) dissolved in distilled water (1.6 mL) was gradually added at -40°C. The reaction temperature was gradually raised to 0°C while stirring for 1 hour. The reaction solution was neutralized with acetic acid, concentrated under reduced pressure, and lyophilized to obtain compound 49 (crude 105.6 mg). EI―MSm / z:1 / 2[M+H]+1406.0,1 / 3[M+H]+937.6.

[0310] Preparation of compound 50 Compound 49 (crude, 105.6 mg) was dissolved in dichloromethane (3.5 mL), and trifluoroacetic acid (0.7 mL) was added at 0° C. and stirred for 3 hours. The reaction solution was concentrated under reduced pressure, purified by HPLC, and lyophilized to obtain compound 50 as a white solid (27 mg, 2 steps 31%). EI―MSm / z:1 / 2[M+H]+1355.9, 1 / 3[M+H]+904.3.

[0311] Example 14: Preparation of Compound 51 [ka]

[0312] Compound 19 (5 g, 10.32 mmol) was dissolved in N,N-dimethylformamide (50 mL), and then propargylamine (0.8 mL, 12.38 mmol), N,N-diisopropylethylamine (3.6 mL, 20.64 mmol), and N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (4.69 g, 12.38 mmol) were added at 0°C under nitrogen atmosphere. The reaction solution was stirred at 0°C for 30 minutes and then at room temperature for 1 hour. Distilled water (50 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (2 x 50 mL). The combined organic layer was dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and purified by column chromatography to obtain compound 51 (4.4 g, 82%). 1 H-NMR(400 MHz, CDCl3)δ 8.07(s,1H),7.58(br,1H),7.05(d,J=8.8Hz,1H),7.03(d,J=8.8Hz,1H),5.42-5.31(m ,4H),4.67(d,J=4.8Hz,2H),4.29-4.13(m,3H),3.75(s,3H),2.24(s,1H),2.06(s,9H).

[0313] Example 15: Preparation of Compound 54 [ka] Preparation of compound 52 Compound 46 (1.73 g, 2.4 mmol) was dissolved in dichloromethane (10 mL) and cooled to 0°C. Di-t-butyl dicarbonate (0.628 g, 2.88 mmol), 4-dimethylaminopyridine (0.058 g, 0.48 mmol), and triethylamine (0.485 g, 4.8 mmol) were added in this order under a nitrogen atmosphere. The temperature was raised to room temperature and the mixture was stirred for about 1 hour. After the reaction was completed, the mixture was diluted with water (10 mL) and extracted with dichloromethane (2 x 50 mL), and the organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Compound 52 (1.33 g, 66%) was obtained by purifying the product by column chromatography. EI―MSm / z:[M+H]+821.9, 1 H-NMR(400 MHz, CDCl3)δ 7.98(d,J=8.4Hz,1H),6.86(t,J=5.6Hz,2H),4.60-4.50(m,1H),4.10(t,J=4.4Hz,2H),3.99(s,2H),3.77(t,J=4.8Hz, 4H),3.74-3.64(m,14H),3.60(t,J=4.8Hz,4H),3.46-3.77(m,8H),2.62-2.58(m,2H),2.40-2.35(m,2H),1.54(s,18H).

[0314] Preparation of compound 53 Compound 52 (500 mg, 0.61 mmol) and compound 51 (700 mg, 1.34 mmol) were dissolved in t-butanol (10 mL), and then copper sulfate (30.4 mg, 0.12 mmol) and sodium ascorbate (121 mg, 0.61 mmol) dissolved in distilled water (10 mL) were added at 0°C.

[0315] Tris(3-hydroxypropyltriazolemethyl)amine (THPTA) (106 mg, 0.24 mmol) was added to the reaction solution and stirred at room temperature under nitrogen atmosphere for 2 hours. The reaction solution was diluted with ethyl acetate (100 mL) and washed with distilled water (70 mL) and saturated sodium chloride solution (70 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure, and then purified by column chromatography to obtain compound 53 (1.12 g, 97%). EI―MSm / z:[M+H]+1864.7,1 / 2[M+H]+932.97, 1H-NMR(400 MHz, CDCl3)δ 8.06―7.95(m,5H),7.85(d,J=2.4Hz,2H),7.48―7.38(m,4H),6.99(d,J=8.4Hz,2H),5.44― 5.25(m,8H),4.77-4.72(m,2H),4.67-4.60(m,6H0,4.56-4.50(m,4H),4.42-4.32(m,1H), 4.30-4.21(m,4H),4.08(t,J=4.8Hz,2H),3.92(s,2H),3.83(t,J=4.8Hz,4H),3.27(t,J=5 .6Hz,4H),2.51-2.47(m,2H),2.36-2.28(m,2H),2.06(s,9H),2.05(s,9H),1.53(s,18H).

[0316] Preparation of compound 54 Compound 53 (1.12 g, 0.60 mmol) and bis(4-nitrophenyl)carbonate (0.64 g, 2.10 mmol) were dissolved in N,N-dimethylformamide (10 mL), and N,N-diisopropylethylamine (0.42 mL, 2.40 mmol) was added at 0°C and stirred at room temperature for 4 hours. The reaction solution was diluted with ethyl acetate (70 mL) and washed with distilled water (3 x 60 mL) and saturated sodium chloride solution (70 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure, and then purified by column chromatography to obtain compound 54 (1.06 g, 81%). EI―MSm / z:[M+H]+2195.3,1 / 2[M+H]+1098.1, 1H-NMR(400 MHz, CDCl3)δ 8.27(d,J=9.28Hz,4H),8.15(d,J=2Hz,2H),7.95-7.89(m,3H),7.79(s,2H),7.54-7.51(m,2H),7.38(d,J=8.8Hz ,4H),7.10-7.02(m,4H),5.44-5.25(m,11H),4.80-4.75(m,2H),4.68-4.63(m,2H),4.58-4.44(m,5H),4.23(d,J= 10Hz,2H),4.09(t,J=4.4Hz,2H),3.95(s,2H),3.88(t,J=5.2Hz,4H),3.79-3.62(m,12H),3.60-3.52(m,8H),3.5 2-3.44(m,5H),3.44-3.33(m,4H),2.62-2.57(m,2H),2.42-2.36(m,2H),2.07(s,9H),2.06(s,9H),1.53(s,18H).

[0317] Example 16: Preparation of Compound 59 [ka] Preparation of compound 58 Compound 55 (300 mg, 0.85 mmol) was dissolved in dichloromethane (3 mL), and then 1-methylimidazole (0.067 mL, 0.85 mmol) and triphosgene (252 mg, 0.85 mmol) were added in this order at 0°C under a nitrogen atmosphere. The reaction solution was stirred for 3 hours, and then 1-methylimidazole (0.2 mL, 2.54 mmol) and triphosgene (90.7 mg, 0.03 mmol) were further added, and the reaction temperature was raised to room temperature and then stirred for 3 hours. The reaction solution was concentrated under reduced pressure and purified by column chromatography to obtain compound 56 (241 mg, 75%).

[0318] Compound 56 obtained above was dissolved in tetrahydrofuran (7 mL), and then compound 57 (456 mg, 0.87 mmol, compound 57 was prepared by the method described in Patent Document 17) and 1-methylimidazole (0.69 mL, 0.87 mmol) were added and the mixture was heated under reflux for 12 hours. The reaction solution was concentrated under reduced pressure and purified by column chromatography to obtain compound 58 (273 mg, 45%). EI-MS m / z: [M+H]+904.5.

[0319] Preparation of compound 59 Compound 58 (270 mg, 0.298 mmol) was dissolved in dichloromethane (3 mL), and then tetrakis(triphenylphosphine)palladium(0) (17.2 mg, 0.015 mmol) and pyrrolidine (0.03 mL, 0.388 mmol) were added at 0°C under a nitrogen atmosphere, and the mixture was stirred at room temperature for 1 hour. The reaction solution was diluted with 0.5N aqueous hydrochloric acid (10 mL), extracted with dichloromethane (20 mL), and then dried over anhydrous sodium sulfate. After filtration, the mixture was concentrated under reduced pressure and purified by column chromatography to obtain compound 59 (250 mg, 97%). EI-MS m / z: [M+H]+864.4.

[0320] Example 17: Preparation of Compound 61 [ka] Preparation of compound 60 Compound 14 (300 mg, 0.47 mmol) was dissolved in tetrahydrofuran (5 mL), and triphenylphosphine (447 mg, 1.70 mmol) and distilled water (0.6 mL) were added. The reaction solution was heated to reflux and stirred for 4 hours. The reaction solution was concentrated under reduced pressure and purified by column chromatography to obtain compound 60 (208 mg, 76%). EI-MS m / z: [M+H]+554.4.

[0321] Preparation of compound 61 Compound 59 (259 mg, 0.30 mmol) and compound 60 (50.3 mg, 0.09 mmol) were dissolved in N,N-dimethylformamide (2 mL), and then N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (204 mg, 0.54 mmol) and N,N-diisopropylethylamine (0.11 mL, 0.63 mmol) were added at 0°C under nitrogen atmosphere. The reaction solution was stirred at room temperature for 72 hours, diluted with saturated aqueous ammonium chloride solution (20 mL), and extracted with ethyl acetate (2 x 20 mL). The combined organic layer was wiped with brine (10 mL) and dried over anhydrous sodium sulfate. After filtration, the mixture was concentrated and purified by column chromatography to obtain compound 61 (100 mg, 36%). EI-MS m / z: 1 / 2[M+H]+1546.4.

[0322] Example 18: Preparation of Compound 62 [ka] Compound 61 (100 mg, 0.032 mmol) was dissolved in methanol / tetrahydrofuran (0.8 mL / 1.6 mL), and then a solution of lithium hydroxide (13.0 mg, 0.32 mmol) dissolved in distilled water (1.6 mL) was gradually added at -40°C. The reaction temperature was gradually raised to 0°C while stirring for 1 hour. The reaction solution was neutralized with acetic acid, concentrated under reduced pressure, and freeze-dried to obtain the hydrolyzed unpurified compound (crude, EI-MS m / z: 1 / 2 [M+H] + 1210.0).

[0323] The compound (crude) obtained above was dissolved in dichloromethane (3.5 mL), and trifluoroacetic acid (0.7 mL) was added at 0° C. and stirred for 3 hours. The reaction solution was concentrated under reduced pressure, purified by HPLC, and lyophilized to obtain compound 62 as a white solid (21 mg, 2 steps 27%). EI―MSm / z:1 / 2[M+H]+1160.04,[M+H]+2319.4.

[0324] Example 19: Preparation of Compound 63 [ka] Compound 56 was dissolved in tetrahydrofuran (7 mL), and then compound 51 (488 mg, 0.935 mmol) and 1-methylimidazole (0.69 mL, 0.87 mmol) were added and the mixture was heated under reflux for 12 hours. The reaction solution was concentrated under reduced pressure and purified by column chromatography to obtain compound 63 (224 mg, 28%). EI-MS m / z: [M+H]+901.6.

[0325] Example 20: Preparation of Compound 65 [ka] Preparation of compound 64 Compound 63 (138 mg, 0.153 mmol) and compound 14 (29.3 mg, 0.046 mmol) were dissolved in t-butanol (1 mL), and then copper sulfate (2.3 mg, 0.009 mmol), sodium ascorbate (9.27 mg, 0.046 mmol), and tris-[1-(3-hydroxypropyl)-1H-[1,2,3]-triazol-4-yl]methyl)amine (THPTA, 8.3 mg, 0.0189 mmol) dissolved in distilled water (1 mL) were added at 0 °C under a nitrogen atmosphere. The reaction solution was stirred at room temperature for 1 hour, and then tetrahydrofuran (0.5 mL) was added and further stirred at room temperature for 5 hours. Anhydrous magnesium sulfate was added to the reaction solution, which was then filtered, concentrated under reduced pressure, and purified by column chromatography to obtain compound 64 (140 mg, 27%). EI-MS m / z: 1 / 2[M+H]+1668.1.

[0326] Preparation of compound 65 Compound 64 (140 mg, 0.04 mmol) was dissolved in methanol / tetrahydrofuran (2 mL / 1 mL), and then a solution of lithium hydroxide (26.0 mg, 0.629 mmol) dissolved in distilled water (3 mL) was gradually added at -40°C. The reaction temperature was gradually raised to 0°C while stirring for 5 hours. The reaction solution was neutralized with acetic acid, concentrated under reduced pressure, and freeze-dried to obtain the hydrolyzed unpurified compound (crude, EI-MS m / z: 1 / 2 [M+H]+ 1331.7).

[0327] The compound (crude) obtained above was dissolved in dichloromethane (4 mL), and trifluoroacetic acid (1 mL) was added at 0° C. and stirred for 4 hours. The reaction solution was concentrated under reduced pressure, purified by HPLC, and lyophilized to obtain compound 65 as a white solid (15.2 mg, 2 steps 14%). EI-MS m / z: 1 / 2[M+H]+1281.7.

[0328] [Preparation of ADCs] The ADCs were prepared through the following two steps, and the commonly used LCB14-0511, LCB14-0512, and LCB14-0606 were prepared by the method described in Patent Document 1. The structural formulae of LCB14-0606, LCB14-0511, and LCB14-0512 are as follows:

[0329] [ka]

[0330] Step 1: Generation of prenylated antibodies The antibody prenylation reaction mixture was prepared and reacted at 30°C for 16 hours. The reaction mixture consisted of 24 μM antibody, 200 nM FTase (Calbiochem #344145), and 0.144 mM LCB14-0511, LCB14-0512, or LCB14-0606 in a buffer solution (50 mM Tris-HCl (pH 7.4), 5 mM MgCl2, 10 μM ZnCl2, 0.5 mM DTT). After the reaction was completed, the prenylated antibody was desalted with a G25 Sepharose column (AKTA purifier, GE Healthcare) equilibrated with PBS buffer solution.

[0331] Step 2: Drug Combination Method <Conjugation by oxime bond formation> The reaction mixture for forming an oxime bond between the prenylated antibody and the linker-drug was prepared by mixing 100 mM Na-acetate buffer solution pH 5.2, 10% DMSO, 24 μM antibody, and 240 μM linker-drug (in-house, the final product of Examples 10, 11, and 13, and the compound in Table 1), and gently stirring at 30° C. After 24 hours of reaction, the excess low molecular weight compound used was removed through an FPLC (AKTA purifier, GE Healthcare) process, and the protein fraction was collected and concentrated.

[0332] <Conjugation by click reaction> The click reaction mixture of the prenylated antibody and the linker-drug was prepared by mixing 10% DMSO, 24 μM antibody, 240 μM linker-drug (in-house), 1 mM copper(II) sulfate pentahydrate, 2 mM (BimC4A)3 (Sigma-Aldrich, 696854), 10 mM sodium ascorbate, and 10 mM aminoguanidine hydrochloride, and reacted at 25°C for 3 hours, and then treated with 2.0 mM EDTA and reacted for 30 minutes. After the reaction was completed, the excess small molecule compound used was removed through an FPLC (AKTA purifier, GE Healthcare) process, and the protein fraction was collected and concentrated.

[0333] [Table 1]

[0334] <Experimental Example 1> In vitro cytotoxicity evaluation The cytostatic activity of the drugs and ADCs listed in Table 2 below against cancer cell lines was measured. As cancer cell lines, commercially available human breast cancer cell lines MCF-7 (HER2 negative or normal), SK-BR3 (HER2 positive), and JIMT-1 (HER2 positive) were used. MMAE was used as the drug, and the ADCs in Table 1 were used as the ADCs. Each cancer cell line was seeded in a 96-well plate at 2,500 to 5,000 cells per well for the 144-hour treatment group and 1,500 to 3,000 cells per well for the 168-hour treatment group, and then cultured for 24 hours. The ADCs and drugs were treated at concentrations of 0.00015 to 10.0 nM (4-fold serial dilution) or 0.0015 to 10 nM (3-fold serial dilution). After 144 / 168 hours, the number of living cells was quantified using SRB (Sulforhodamine B) dye.

[0335] [Table 2]

[0336] It was confirmed that ADC1, ADC2, and ADC3 have excellent cytotoxicity in breast cancer cell lines.

[0337] Those skilled in the art will recognize or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific embodiments of the present invention described herein. Such equivalents are intended to be included within the scope of the claims. The above description of the present invention is merely illustrative, and those skilled in the art will understand that the present invention can be easily modified into other specific forms without changing the technical spirit or essential characteristics of the present invention. Therefore, the above-described embodiments are merely illustrative in all respects and are not limiting. For example, each component described as being of a single type may be implemented in a distributed manner, and similarly, components described as being distributed may also be implemented in a combined form. Any modifications or variations derived from the meaning and scope of the claims and their equivalent concepts may be construed as being included within the scope of the present invention. [Industrial Applicability]

[0338] The ligand-drug conjugate according to one embodiment of the present invention may include a linker containing a Tris structure, and the active agent is bound by the Tris structure, so that a larger number of active agents can be linked through one linker. That is, a larger number of active agents can be delivered to a target cell per ligand binding. Therefore, the ligand-drug conjugate of the present invention can effectively, specifically, and selectively deliver a drug, and can stably reach a target cell during circulation in the body, and the drug can be easily released after reaching the target cell. In addition, the linker according to one embodiment of the present invention includes a trigger unit that can easily release the drug in the target cell to maximize the drug effect, and the drug and / or toxin can stably reach the target cell to effectively exert the drug effect, and can be used in the technical field.

Claims

1. A first branched linker BL that is attached to an active agent 1 , the first branched linker BL 2 and a first branched linker BL 3 Two of them, a second linker (SL) linked to the nitrogen of the tris structure and linked to an antibody; A linker for a ligand-drug complex having a tris structure represented by the following general formula 5A or 6A. In the general formula 5A and the general formula 6A, The first branched linker BL 1 , the first branched linker BL 2 and a first branched linker BL 3 two of the first and second inputs include one or more of a branching unit (BR), a connection unit, or a binding unit; the second linker comprises one or more linking units; The branching unit is at least one amino acid, -C(O)-, or represented by the following general formula 3B: In the general formula 3B, R 4 is hydrogen or -L 4 -COOR 5 And L 4 is a direct bond or -C n H 2n -, n is an integer from 1 to 10, R 5 is hydrogen or C 1 -C 30 is alkyl, The linking unit is -(CH 2 ) r (V(CH 2 ) p ) q -, -((CH 2 ) p V) q -, -(CH 2 ) r (V(CH 2 ) p ) q Y-, -((CH 2 ) p V) q (CH 2 ) r -, -Y((CH 2 ) p V) q - or - (CH 2 ) r (V(CH 2 ) p ) q YCH 2 -, where r is an integer from 0 to 10, p is an integer from 1 to 10, q is an integer from 1 to 20, V is a single bond, -O-, or -S-, and Y is a single bond, -O-, -S-, -NR 21 --, --C(O)NR 22 --, --NR 23 C(O)-, -NR 24 SO 2 - or -SO 2 N.R. 25 - and R 21 ~R 25 are each independently hydrogen or (C 1 -C 6 ) alkyl; The linking unit is represented by any one of the following general formulas 1D to 4D: In the above general formulae 1D to 4D, L 1 is a single bond or an alkylene having 1 to 30 carbon atoms; R 11 is hydrogen or alkyl having 1 to 10 carbon atoms; L 2 is an alkylene having 1 to 30 carbon atoms.

2. The linker for a ligand-drug conjugate according to claim 1, wherein the linker comprises at least one polyalkylene glycol unit.

3. 2. The linker for a ligand-drug conjugate of claim 1, wherein the linker comprises any atom or group that allows three bonds, such as an amine, a tertiary amide, or a tertiary or quaternary carbon.

4. The linker for a ligand-drug conjugate according to claim 1, wherein the linker comprises a substituted or unsubstituted alkylene having 1 to 100 carbon atoms and satisfies one or more of the following conditions (i) to (iii): (i) the alkylene contains at least one heteroarylene; (ii) at least one carbon atom of the alkylene is replaced by one or more atoms selected from nitrogen (N), oxygen (O) and sulfur (S); (iii) the alkylene is substituted with one or more alkyl groups having 1 to 20 carbon atoms.

5. A ligand; a second linker (SL) covalently linked to the ligand and attached to the nitrogen of the tris structure; A linker including a Tris structure represented by the following general formula 5A or 6A, First branched linker BL 1 , the first branched linker BL 2 and a first branched linker BL 3 and an active agent covalently linked to two of said ligand-drug conjugates. In the general formula 5A and the general formula 6A, The first branched linker BL 1 , the first branched linker BL 2 and a first branched linker BL 3 two of the first and second inputs include one or more of a branching unit (BR), a connection unit, or a binding unit; the second linker comprises one or more linking units; The branching unit is at least one amino acid, -C(O)-, or represented by the following general formula 3B: In the general formula 3B, R 4 is hydrogen or -L 4 -COOR 5 And L 4 is a direct bond or -C n H 2n -, n is an integer from 1 to 10, R 5 is hydrogen or C 1 -C 30 is alkyl, The linking unit is -(CH 2 ) r (V(CH 2 ) p ) q -, -((CH 2 ) p V) q -, -(CH 2 ) r (V(CH 2 ) p ) q Y-, -((CH 2 ) p V) q (CH 2 ) r -, -Y((CH 2 ) p V) q - or - (CH 2 ) r (V(CH 2 ) p ) q YCH 2 -, where r is an integer from 0 to 10, p is an integer from 1 to 10, q is an integer from 1 to 20, V is a single bond, -O-, or -S-, and Y is a single bond, -O-, -S-, -NR 21 --, --C(O)NR 22 --, --NR 23 C(O)-, -NR 24 SO 2 - or -SO 2 N.R. 25 - and R 21 ~R 25are each independently hydrogen or (C 1 -C 6 ) alkyl; The linking unit is represented by any one of the following general formulas 1D to 4D: In the above general formulae 1D to 4D, L 1 is a single bond or an alkylene having 1 to 30 carbon atoms; R 11 is hydrogen or alkyl having 1 to 10 carbon atoms; L 2 is an alkylene having 1 to 30 carbon atoms.

6. The ligand-drug conjugate of claim 5, wherein said branching unit is represented by at least one or more L- or D-amino acids.

7. The ligand-drug conjugate of claim 5, wherein said branching unit is represented by at least one or more α- or β-amino acids.

8. The ligand-drug conjugate according to claim 5, wherein the branching unit is represented by at least one amino acid selected from the group consisting of lysine, 5-hydroxylysine, 4-oxalyl lysine, 4-thialysine, 4-selenalysine, 4-thiahomolesine, 5,5-dimethyllysine, 5,5-difluorolysine, trans-4-dehydrolysine, 2,6-diamino-4-hexanoic acid, cis-4-dehydrolysine, 6-N-methyllysine, diaminopimelic acid, ornithine, 3-methylornithine, α-methylornithine, citrulline, and homocitrulline.

9. 6. The ligand-drug conjugate of claim 5, wherein said branching unit is represented by at least one hydrophilic amino acid.

10. 6. The ligand-drug conjugate of claim 5, wherein the branching unit is represented by at least one hydrophilic amino acid containing a side chain having a residue that is charged in aqueous solution at neutral pH.

11. 6. The ligand-drug conjugate of claim 5, wherein the branching unit is represented by at least one or more of arginine, aspartic acid, asparagine, glutamic acid, glutamine, histidine, lysine, ornithine, proline, serine, or threonine.

12. The linking unit is -(CH 2 ) r (V(CH 2 ) p ) q -, where r is an integer from 0 to 10, p is an integer from 0 to 12, q is an integer from 1 to 20, and V is a single bond, -O-, or -S-.

13. The ligand-drug conjugate of claim 5, wherein the linking unit is represented by a polyethylene glycol unit having the structure of the following general formula 5 or 6:

14. The linking unit is 1 to 12 -OCH 2 CH 2 The ligand-drug conjugate of claim 5, wherein the ligand-drug conjugate is represented by - units.

15. The linking unit is -(CH 2 CH 2 6. The ligand-drug conjugate of claim 5, represented by X) w-, where X is a single bond or --O--, and w is an integer from 1 to 20.

16. The ligand-drug conjugate according to claim 5, wherein the linker comprises an isoprenyl unit represented by the following general formula 7, and n is an integer of 2 or more. [C33]

17. The ligand-drug conjugate of claim 5, wherein the linker comprises any one of units of the following general formulas 4A to 6A: In the following general formulas 4A to 6A, V represents a single bond, —O—, or —S—; r is an integer from 0 to 10; p is an integer from 1 to 10; q is an integer from 1 to 20; L 1 is a single bond.

18. The linker for a ligand-drug conjugate according to claim 5, which contains at least one substituted or unsubstituted alkylene having 1 to 100 carbon atoms and satisfies one or more of the following conditions (i) to (iii): (i) the alkylene contains at least one heteroarylene; (ii) at least one carbon atom of the alkylene is replaced by one or more atoms selected from nitrogen (N), oxygen (O) and sulfur (S); (iii) the alkylene is substituted with one or more alkyl groups having 1 to 20 carbon atoms.

19. The ligand-drug conjugate of claim 5, wherein the linker is covalently attached to the ligand by a thioether bond, the thioether bond involving a sulfur atom of a cysteine ​​of the ligand.

20. 6. The ligand-drug conjugate of claim 5, wherein the ligand comprises a C-terminal amino acid motif that is recognized by an isoprenoid transferase.

21. The amino acid motif is a CYYX sequence, C represents cysteine, Each Y independently represents an aliphatic amino acid; The ligand-drug conjugate of claim 20, wherein each X independently represents glutamine, glutamic acid, serine, cysteine, methionine, alanine, or leucine.

22. 21. The ligand-drug conjugate of claim 20, wherein the amino acid motif is a CVIM or CVLL sequence.

23. The ligand-drug conjugate of claim 5, wherein the active agent is linked to the linker by a cleavable or non-cleavable bond, hydrolyzable or non-hydrolyzable bond.

24. The ligand-drug conjugate of claim 5, wherein the active agent is linked to the linker via a trigger unit represented by the following general formula 3F or 4F: (wherein, in general formula 3F or general formula 4F, G is a sugar, sugar acid, or sugar derivative; W is -C(O)-, -C(O)NR'-, -C(O)O-, -S(O) 2 NR'-, -P(O)R''NR'-, -S(O)NR'-, or -PO 2 When C(O), S, or P is directly attached to the phenyl ring, R′ and R″ are each independently hydrogen, (C 1 -C 8 ) alkyl, (C 3 -C 8 ) cycloalkyl, (C 1 -C 8 ) alkoxy, (C 1 -C 8 ) alkylthio, mono- or di-(C 1 -C 8 ) alkylamino, (C 3 -C 20 ) heteroaryl, or (C 6 -C 20 ) aryl; Each Z is independently hydrogen, (C 1 -C 8) alkyl, halogen, cyano or nitro; n is an integer from 1 to 3, R 1 and R 2 are each independently hydrogen, (C 1 -C 8 ) alkyl or (C 3 -C 8 ) cycloalkyl, or R 1 and R 2 are attached to the carbon atom (C 3 -C 8 ) forming a cycloalkyl ring, L represents a linker linkage. B is an activator.

25. 25. The ligand-drug conjugate of claim 24, wherein the sugar or sugar acid is a monosaccharide.

26. The ligand-drug conjugate of claim 24, wherein G is represented by the following general formula 2F: In the above general formula 2F, R 3 is hydrogen or a carboxyl protecting group, R 4 are each independently hydrogen or a hydroxyl protecting group.

27. The ligand-drug conjugate of claim 24, wherein W is -C(O)NR'-, where C(O) is connected to a phenyl ring and NR' is connected to a linker, and G is represented by the following general formula 2F: In the above general formula 2F, R 3 is hydrogen or a carboxyl protecting group, R 4 are each independently hydrogen or a hydroxyl protecting group.

28. The ligand-drug conjugate of claim 5, wherein the active agent is a drug, a toxin, an affinity ligand, or a detection probe.

29. 6. The ligand-drug conjugate of claim 5, wherein the active agent is an immunomodulatory compound, an anti-cancer agent, an anti-viral agent, an anti-bacterial agent, an anti-fungal agent, or an anti-parasitic agent.

30. The ligand-drug conjugate of claim 5, wherein the active agent is selected from the active agents listed below: (a) erlotinib, bortezomib, fulvestrant, sutent, letrozole, imatinib mesylate, PTK787 / ZK 222584, oxaliplatin, 5-fluorouracil, leucovorin, rapamycin, lapatinib, lonafarnib, sorafenib, gefitinib, AG1478, AG1571, thiotepa hiotepa), cyclophosphamide, busulfan, improsulfan, piposulfan, benzodopa, carboquone, meturedopa, uredopa, ethyleneimine, a Altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, trimethylolomelanine, bullatacin , bullatacinone, camptothecin, topotecan, bryostatin, callystatin, CC-1065, adozelesin, carzelesin, bizelesin, cryptophycin 1, cryptophycin 88), dolastatin, duocarmycin, KW-2189, CB1-TM1, eleutherobin, pancratistatin, sarcodictyin, spongistatin, chlorambucil, chlornaphazine, chlorophosphamide, cholophosphamide, estramustine, ifosfamide, mechlorethamine, melphalan, novembichine, phenesterine, prednimustine, trofosfamide, uracil mustard, mustard, carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimnustine, calicheamicin, calicheamicin gamma 1, calicheamicin omega 1, dynemicin, dynemicin A, clodronate, esperamicin, neocarzinostatin chromophorechromophore), aclacinomycins, actinomycin, anthramycin, azaserine, bleomycins, cactinomycin, carabicin, carninomycin, carzinophilin, chromomycins, dactinomycin, daunol bicine, detorubicine, 6-diazo-5-oxo-L-norleucine, doxorubicin, morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin, liposomal doxorubicin doxorubicin, deoxydoxorubicin, epirubicin, esorubicin, marcellomycin, mitomycin C, mycophenolic acidacid), nogalamycin, olivomycin, peplomycin, potfilomycin, puromycin, queramycin, rodorubicin, streptomigrin, streptozocin, tubercidin , ubenimex, zinostatin, zorubicin, 5-fluorouracil, denopterin, methotrexate, pteropterin, trimetrexate, fludarabine, 6-mercaptopurine, Thiamiprine, thiguanine, ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, xuridine, calusterone, dromostanolone, propionate, epithiostanol, mepitiostane, testolactone, aminoglutethimide, mitotane, trilostane, folinic acid, aceglatone, aldophosphamide glycoside, aminolevulinic acidacid), eniluracil, amsacrine, bestrabucil, bisantrene, edatraxate, defofamine, demecolcine, diaziquone, elfornithine, elliptinium acetate, etoglucid, gallium nitrate nitrate, hydroxyurea, lentinan, lonidainine, maytansine, ansamitocins, mitoguazone, mitoxantrone, mopidanmol, nitraerine, pentostatin, phenameth henamet), pirarubicin, losoxantrone, 2-ethylhydrazide, procarbazine, polysaccharide K, razoxane, rhizoxin, sizofiran, spirogermanium, tenuazonic acid acid), triaziquone, 2,2',2''-trichlorotriethylamine, T-2 toxin, verracurin A, roridin AA), anguidine, urethane, vindesine, dacarbazine, mannomustine, mitobronitol, mitolactol, pipobroman, gacytosine, arabinoside, cyclophosphamide, thiotepa, albumin-engineered nanoparticle formulation of paclitaxel paclitaxel), docetaxel, chlorambucil, gemcitabine, 6-thioguanine, mercaptopurine, cisplatin, carboplatin, vinblastine, platinum, etoposide, ifosfamide, mitoxantrone, vincristine, stine, vinorelbine, novantrone, teniposide, edatrexate, daunomycin, aminopterin, xeloda, ibandronate, CPT-11, the topoisomerase inhibitor RFS 2000, difluoromethylornithine, retinoic acid, capecitabine, or a pharma- ceutically acceptable salt, solvate, or acid thereof; (b) monokines, lymphokines, polypeptide hormones, parathyroid hormones, thyroxine, relaxin, prorelaxin, glycoprotein hormones, follicle stimulating hormone, thyroid stimulating hormone, luteinizing hormone, hepatic growth factor, fibroblast growth factor growth factor, prolactin, placental lactogen, tumor necrosis factor-α, tumor necrosis factor-β, Mullerian-inhibiting substance, mouse gonadotropin-associated peptide, inhibin, activin, vascular endothelial growth factor factor), thrombopoietin, erythropoietin, osteoinductive factor, interferon, interferon-α, interferon-β, interferon-γ, colony stimulating factor;CSF), macrophage-CSF, granulocyte-macrophage-CSF, granulocyte-CSF, interleukin (IL), IL-1, IL-1 alpha, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, tumor necrosis factor, TNF-alpha, TNF-beta, polypeptide factor, LIF, kit ligand, or combinations thereof; (c) diphtheria toxin, botulinum toxin, tetanus toxin, dysenteriatoxin, cholera toxin, amanitin, α-amanitin, pyrrolobenzodiazepine, pyrrolobenzodiazepine derivatives, tetrodotoxin, brevetoxin, ciguatoxin, ricin, AM toxin, auristatin, tubulysin, Geldanamycin, maytansinoids, calicheamicin, daunomycin, doxorubicin, methotrexate, vindesine, SG2285, dolastatin, dolastatin analogs analog), auristatin, cryptophycin, camptothecin, rhizoxin, rhizoxin derivatives, CC-1065, CC-1065, analogs or derivatives, duocarmycin, enediyne antibiotic, esperamicin, epothilone, toxoid, or combinations thereof; (d) an affinity ligand; wherein the affinity ligand is a substrate, an inhibitor, an activator, a neurotransmitter, a radioisotope, or a combination thereof; (e) a radioactive label, 32P, 35S, a fluorescent dye, an electron dense reagent, an enzyme, biotin, streptavidin, digoxigenin, a hapten, an immunogenic protein, a nucleic acid molecule with a sequence complementary to a target, or a combination thereof; (f) immunomodulatory compounds, anti-cancer agents, anti-viral agents, anti-bacterial agents, anti-fungal agents, and anti-parasitic agents, or combinations thereof; (g) tamoxifen, raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone or toremifene; (h) 4(5)-imidazole, aminoglutethimide, megestrol acetate, exemestane, letrozole, or anastrozole; (i) flutamide, nilutamide, bicalutamide, leuprolide, goserelin, or troxacitabine; (j) aromatase inhibitors; (k) a protein kinase inhibitor; (l) a lipid kinase inhibitor; (m) shRNA, siRNA, PNA or antisense oligonucleotide; (n) a ribozyme; (o) vaccines; (p) angiogenesis inhibitors, and (q) immuno-oncology therapeutic agents.

31. The ligand-drug conjugate according to claim 5, wherein the linker is any one of the structures of the following general formulas 8 to 13: (wherein * indicates the site to be linked to the activator, n and m are each independently an integer from 1 to 20.

32. The ligand-drug conjugate of claim 5 , wherein the linker is attached to the C-terminus of the ligand.

33. 33. A pharmaceutical composition for preventing or treating hyperproliferative, cancer or angiogenic diseases, comprising as an active ingredient the ligand-drug conjugate or a pharma- ceutically acceptable salt or solvate thereof according to any one of claims 5 to 32.

34. 34. The pharmaceutical composition of claim 33, wherein the composition further comprises a therapeutically effective amount of a chemotherapeutic agent.

35. 34. The pharmaceutical composition of claim 33, wherein the cancer is selected from the group consisting of lung cancer, small cell lung cancer, gastrointestinal cancer, colon cancer, intestinal cancer, breast cancer, ovarian cancer, prostate cancer, testicular cancer, liver cancer, kidney cancer, bladder cancer, pancreatic cancer, brain cancer, sarcoma, osteosarcoma, Kaposi's sarcoma, and malignant melanoma.

Citation Information

Patent Citations

  • Trimaleimide-type linker and application thereof

    JP2018515610A

  • Compound bearing beta-galactoside-introduced self-immolative linker

    WO2018124758A2

  • Pyrrolobenzodiazepine dimer precursor and ligand-linker conjugate compound thereof

    WO2018182341A1

  • Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents

    EP1391213A1

  • KR2014